News

View

Sort By

Sep 22, 2021

Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease

Sep 22, 2021

Synlogic Announces Pricing of Public Offering of Common Stock

Sep 21, 2021

VectivBio Announces Closing of Comet Therapeutics Acquisition

Sep 20, 2021

ADAGIO THERAPEUTICS PROVIDES COVID-19 ANTIBODY PROGRAM UPDATES AS WELL AS BUSINESS HIGHLIGHTS AND SECOND QUARTER 2021 FINANCIAL RESULTS

Sep 20, 2021

Verrica Pharmaceuticals Receives Complete Response Letter from the FDA identifying deficiencies at a facility of a Contract Manufacturer for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Sep 20, 2021

Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria

Sep 20, 2021

Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer

Sep 20, 2021

Ventyx Biosciences Announces Key Appointments and Closing of $51.0 Million Series B Convertible Preferred Stock Financing Round

Sep 16, 2021

Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors

Sep 16, 2021

Repligen Announces Agreement to Acquire Avitide Inc.

Sep 15, 2021

CRINETICS PHARMACEUTICALS� ORAL SST5 AGONIST CRN04777 DEMONSTRATED PHARMACOLOGIC PROOF-OF-CONCEPT WITH STRONG DOSE-DEPENDENT SUPPRESSION OF INSULIN SECRETION IN PHASE 1 SINGLE ASCENDING DOSE STUDY

Sep 15, 2021

Alpine Immune Sciences Announces $91 Million Private Placement

Sep 13, 2021

BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough

Sep 13, 2021

Adicet Bio Collaborates with Twist Bioscience to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics

Sep 10, 2021

scPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the�Heart Failure Society of America Annual Scientific Meeting 2021

Sep 9, 2021

Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing Loss

Sep 9, 2021

Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins

Sep 8, 2021

ADARx Raises $75 Million to Advance Growing Pipeline

Sep 2, 2021

CRINETICS PHARMACEUTICALS EXPANDS EXECUTIVE TEAM WITH ADDITION OF JEFF KNIGHT AS CHIEF OPERATING OFFICER

Sep 2, 2021

Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases

Aug 31, 2021

RayzeBio Expands Leadership Team with Susan Moran, M.D., as Chief Medical Officer; Kimberly Ma, M.S., as SVP of Clinical Operations; and Nicholas Smith, Ph.D., as SVP of Chemistry Innovation

Aug 26, 2021

Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders

Aug 26, 2021

Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement

Aug 25, 2021

CTI BioPharma and DRI Healthcare Trust Announce up to $135 Million Debt and Royalty Transaction

Aug 23, 2021

Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Dr. Christopher Kenney as Chief Medical Officer

Aug 17, 2021

Fertility Startup Carrot Raises $75 Million In A Series C Round Led By Tiger Global

Aug 17, 2021

Sparrow Pharmaceuticals Expands Executive Leadership With Appointment of Frank Czerwiec, MD as Chief Medical Officer and Jamie MacPherson, PharmD as Vice President of Regulatory Affairs and Quality

Aug 16, 2021

Aerin Medical Announces Positive One-Year Results from RhinAer� Pivotal Trial for the Treatment of Chronic Rhinitis

Aug 12, 2021

Acutus Medical Reports Second Quarter 2021 Financial Results

Aug 12, 2021

NeuroPace Reports Second Quarter 2021 Financial Results

Aug 11, 2021

GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation

Aug 11, 2021

TELA Bio Reports Record Second Quarter 2021 Revenues�Driven by Increased Demand

Aug 11, 2021

Neurelis Secures Senior Term Loan Facility Of Up To $150 Million From Orbimed

Aug 10, 2021

ADAGIO THERAPEUTICS ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING AND FULL EXERCISE OF UNDERWRITERS� OPTION TO PURCHASE ADDITIONAL SHARES

Aug 10, 2021

Augmedix Reports Second Quarter 2021 Financial Results

Aug 10, 2021

CRINETICS PHARMACEUTICALS� ORAL ACTH ANTAGONIST, CRN04894, DEMONSTRATES PHARMACOLOGICPROOF-OF-CONCEPT WITH STRONG DOSE-DEPENDENT CORTISOL SUPPRESSION IN PHASE 1 SINGLE ASCENDING DOSE STUDY

Aug 9, 2021

Sierra Oncology Provides Update to Momelotinib Development Timeline and Closes on $34 Million in Additional Funding

Aug 5, 2021

Sonendo� Appoints Michael Smith as Chief Commercial Officer

Aug 5, 2021

Kala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Aug 5, 2021

Oyster Point Pharma Reports Second Quarter 2021 Financial Results and Recent Business Highlights

Aug 5, 2021

Positive Aerin Medical AERWAY Study Results Published Showing Effectiveness of VivAer� For Nasal Obstruction Patients with Nasal Valve Collapse

Aug 2, 2021

Keros Therapeutics Appoints Simon Cooper, M.B.B.S. as Chief Medical Officer

Jul 30, 2021

ENYO Pharma Announces 16 Weeks Vonafexor (EYP001) Top-Line Interim Results from Two on-going Phase 2a Studies in Chronic Hepatitis B Patients

Jul 29, 2021

CRINETICS PHARMACEUTICALS ANNOUNCES $15.0 MILLION PRIVATE PLACEMENT WITH FRAZIER HEALTHCARE PARTNERS

Jul 29, 2021

Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses

Jul 29, 2021

Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors

Jul 28, 2021

ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks

Jul 27, 2021

SpringWorks Therapeutics Appoints Dr. James Cassidy as Chief Medical Officer

Jul 16, 2021

ReViral Announces Positive Recommendation by the Data Safety Monitoring Committee to Continue the Phase 2 Clinical Study of Sisunatovir for Treatment of Respiratory Syncytial Virus Infections in Hospitalized Infants

Jul 15, 2021

Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU)

Jul 14, 2021

Acutus Medical, Inc. Announces Pricing of Public Offering of Common Stock

Jul 14, 2021

TransMedics Announces Positive FDA Advisory Committee Vote for the OCS Liver System

Jul 13, 2021

Aerin Medical Announces Results of Randomized Controlled Trial Supporting VivAer� for Treatment of Nasal Airway Obstruction with Nasal Valve Collapse

Jul 13, 2021

IMARA ANNOUNCES PRICING OF PUBLIC OFFERING

Jul 12, 2021

Acutus Medical Reports Preliminary Unaudited Second Quarter 2021 Financial Results

Jul 12, 2021

Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis

Jul 7, 2021

Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate

Jul 7, 2021

SCORPION THERAPEUTICS ANNOUNCES NEW CEO AXEL HOOS, M.D., PH.D.

Jul 6, 2021

NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors

Jul 1, 2021

Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo

Jun 29, 2021

Harmony Biosciences Initiates A Phase 2 Clinical Trial In Myotonic Dystrophy

Jun 28, 2021

CRINETICS PHARMACEUTICALS�ANNOUNCES�DOSING OF�FIRST PATIENT IN�PHASE 3 PATHFNDR-1 STUDY EVALUATING�ORAL�PALTUSOTINE�FOR THE�TREATMENT�OF�ACROMEGALY

Jun 28, 2021

ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

Jun 24, 2021

Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of AGLE-177, a Potential First-in-Class Treatment for Homocystinuria

Jun 24, 2021

TERNS ANNOUNCES INITIATION OF PATIENT DOSING IN AVIATION PHASE 1B NASH CLINICAL TRIAL OF VAP-1 INHIBITOR TERN-201

Jun 24, 2021

Alpine Immune Sciences Announces First Patient Dosed in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial and $45 million in Development Milestones Achieved Under AbbVie Collaboration

Jun 24, 2021

VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease

Jun 23, 2021

ADELA DEBUTS WITH $60M IN SERIES A FINANCING AND A BREAKTHROUGH APPROACH TO BLOOD-BASED DETECTION OF CANCER AND OTHER DISEASES

Jun 22, 2021

Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Jun 22, 2021

Galecto�s GB0139 Shows Favorable Safety and Tolerability Profile with Promising Changes in Efficacy Markers in Hospitalized COVID-19 Patients

Jun 22, 2021

Keros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

Jun 22, 2021

AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada

Jun 21, 2021

Sierra Oncology Announces Completion of Enrollment for MOMENTUM Phase 3 Trial

Jun 17, 2021

Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer

Jun 17, 2021

Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease

Jun 16, 2021

ReViral Announces Positive Recommendation by the Data Safety Monitoring Committee to Continue the Phase 2 Clinical Study of Sisunatovir for Treatment of Respiratory Syncytial Virus Infections in Hospitalized Infants

Jun 15, 2021

SpringWorks Therapeutics Announces Presentation of Updated Interim Data from the Phase 2b ReNeu Trial at the 2021 Children�s Tumor Foundation NF Conference

Jun 15, 2021

VectivBio Announces First Patient Dosed in Metabolic Balance Study of Apraglutide in Colon-in-Continuity Patients with Short Bowel Syndrome with Intestinal Failure

Jun 14, 2021

TERNS REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 2A LIFT STUDY OF FXR AGONIST TERN-101 IN PATIENTS WITH NASH

Jun 11, 2021

X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenstr�m�s Macroglobulinemia at EHA 2021

Jun 11, 2021

IMARA PRESENTS CLINICAL DATA ON IMR-687 IN SICKLE CELL DISEASE AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) ANNUAL CONGRESS

Jun 10, 2021

Janux Therapeutics Announces Pricing of Initial Public Offering

Jun 10, 2021

89bio Initiates Phase 2b ENLIVEN Trial of BIO89-100 for the Treatment of NASH

Jun 10, 2021

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China

Jun 8, 2021

Neurogastrx Announces Agreement with Daewoong Pharmaceutical to Develop Fexuprazan for Treatment of Acid-Related GI Disorders in the U.S.

Jun 7, 2021

SpringWorks Therapeutics Announces Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA in Patients with Relapsed or Refractory Multiple Myeloma

Jun 4, 2021

Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl�s CLN-081 in NSCLC EGFR Exon 20 Patients

Jun 4, 2021

HARPOON THERAPEUTICS PRESENTS UPDATED INTERIM CLINICAL DATA FOR THE PSMA-TARGETING TRITAC� HPN424 AT THE 2021 ASCO ANNUAL MEETING

Jun 3, 2021

Kala Pharmaceuticals Announces EYSUVIS� Now Covered by OptumRx

Jun 2, 2021

ereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS)

Jun 2, 2021

ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel

Jun 1, 2021

CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis

May 28, 2021

Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum

May 27, 2021

binx health Raises $104 Million in Series E Financing

May 25, 2021

Turning Point Therapeutics Names Former Celgene Chairman and CEO, Mark Alles, to Chair Its Board of Directors

May 18, 2021

Sparrow Pharmaceuticals Secures $50 Million Series A Financing

May 17, 2021

Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business Officer

May 17, 2021

Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement

May 13, 2021

Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.

May 13, 2021

Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture

May 12, 2021

X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenstr�m�s Macroglobulinemia as Published in EHA Abstract

May 12, 2021

Acutus Medical Announces CE Mark Approval for Suite of Next Generation EP Products in Europe

May 12, 2021

Graybug Vision Reports Full-Data Analysis from 12-Month Treatment Phase of ALTISSIMO Phase 2b Trial in Wet AMD

May 6, 2021

Valneva Announces the Pricing of its Initial Public Offering on Nasdaq

May 6, 2021

AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy

May 6, 2021

SpringWorks Therapeutics Expands Targeted Oncology Pipeline with Exclusive Worldwide License to TEAD Inhibitor Portfolio

May 5, 2021

Adagio Therapeutics Announces ADG20 Phase 1 Data and Initiation of Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19

May 4, 2021

Theseus Pharmaceuticals Appoints Tim Clackson, Ph.D., as Chief Executive Officer

May 4, 2021

Ventyx Biosciences Appoints Martin D. Auster, M.D. as Chief Financial Officer

May 4, 2021

New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials

May 3, 2021

Aeglea BioTherapeutics Completes Patient Randomization for PEACE, its Pivotal Phase 3 Clinical Trial of Pegzilarginase for the Treatment of Arginase 1 Deficiency

May 3, 2021

Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors

Apr 27, 2021

Edgewise Therapeutics Appoints Joanne Donovan, M.D., Ph.D., as Chief Medical Officer

Apr 26, 2021

Procter & Gamble Veteran Jane Wildman Joins Gelesis Board of Directors

Apr 26, 2021

NeuroPace, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters� Option to Purchase Additional Shares

Apr 21, 2021

Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001

Apr 20, 2021

Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials

Apr 19, 2021

Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19

Apr 16, 2021

Synlogic Announces Pricing of Public Offering of Common Stock

Apr 14, 2021

AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration

Apr 13, 2021

Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors

Apr 12, 2021

Valneva Completes Recruitment for Pivotal Phase 3 Trial of Chikungunya Vaccine Candidate and Initiates Antibody Persistence Trial

Apr 10, 2021

Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001

Apr 10, 2021

Valneva Files Registration Statement for Proposed United States Initial Public Offering

Apr 8, 2021

SCORPION THERAPEUTICS APPOINTS GUY PADBURY, PH.D. AS CHIEF DEVELOPMENT OFFICER

Apr 7, 2021

Nucleix Secures $55 Million Funding to Advance Lung EpiCheck® for Early Detection of Lung Cancer

Apr 6, 2021

TransMedics Announces Positive FDA Advisory Committee Vote for OCS Heart System

Apr 6, 2021

Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001

Apr 5, 2021

Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of RET Inhibitor TPX-0046

Apr 5, 2021

Published Peer-Reviewed Data Demonstrate Bamlanivimab�s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19

Apr 1, 2021

AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration

Apr 1, 2021

Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., To Board Of Directors

Mar 31, 2021

Turning Point Therapeutics Announces Board Changes

Mar 31, 2021

Scribe Therapeutics Raises $100M Series B Financing to Further Develop �CRISPR by Design� Platform and Pipeline of Breakthrough Genetic Medicines

Mar 25, 2021

Fusion Pharmaceuticals Announces Fourth Quarter 2020 Financial Results And Business Update

Mar 25, 2021

Ikena Oncology Announces Pricing of Initial Public Offering

Mar 25, 2021

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Mar 25, 2021

Edgewise Therapeutics Announces Pricing of Initial Public Offering

Mar 25, 2021

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

Mar 24, 2021

TELA Bio Announces Fourth Quarter and Full Year 2020 Financial Results

Mar 24, 2021

89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Mar 24, 2021

BELLUS Health Appoints William Mezzanotte, MD, MPH to its Board of Directors

Mar 24, 2021

HARPOON THERAPEUTICS APPOINTS EXPERIENCED BIOTECH LEADER ALAN COLOWICK, M.D., TO BOARD OF DIRECTORS

Mar 23, 2021

scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Mar 23, 2021

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update

Mar 22, 2021

Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East

Mar 22, 2021

TERNS ANNOUNCES INITIATION OF DOSING IN PHASE 1 CLINICAL TRIAL OF TERN-501, ITS THR-BETA AGONIST IN DEVELOPMENT FOR THE TREATMENT OF NASH

Mar 22, 2021

Passage Bio Appoints Eliseo O. Salinas, M.D., MSc, as Chief Research & Development Officer

Mar 22, 2021

SpringWorks Therapeutics Appoints Bhavesh Ashar as Chief Commercial Officer

Mar 22, 2021

Phase 1 Trial Demonstrates Encouraging Clinical Benefit and Promising Safety Profile of Pacritinib for the Prevention of Graft-Versus-Host Disease Published in Clinical Cancer Research

Mar 22, 2021

Verrica Announces Pricing of Public Offering of Common Stock

Mar 21, 2021

Augmedix Announces Preliminary Fourth Quarter and Full Year 2020 Results

Mar 19, 2021

X4 Pharmaceuticals Announces $55.0 Million At-the-Market Private Placement Financing

Mar 18, 2021

Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo

Mar 18, 2021

TELA Bio Announces 12-Month Analysis from BRAVO Study of OviTex� for Ventral Hernia Repair

Mar 18, 2021

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

Mar 18, 2021

Janux Therapeutics Appoints Vickie Capps and Dr. Sheila Gujrathi to Board of Directors

Mar 18, 2021

Acutus Medical Board Appoints John Sheridan as a New Director

Mar 18, 2021

Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Mar 18, 2021

Acutus Medical Reports Fourth Quarter and Full Year 2020 Financial Results

Mar 17, 2021

Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Commercialize VP-102 For Molluscum and Common Warts in Japan

Mar 17, 2021

CTI BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results

Mar 17, 2021

Harmony Biosciences Highlights Publication Of Wakix� (Pitolisant) Efficacy Data In Sleep Medicine

Mar 16, 2021

Kala Pharmaceuticals Announces Preferred Position for EYSUVIS� on Cigna

Mar 16, 2021

Ventyx Biosciences Doses First Subject in a Phase 1 Trial of VTX-958, a Selective Allosteric TYK2 Inhibitor for Autoimmune Diseases

Mar 16, 2021

Janux Therapeutics Appoints Andy Meyer Chief Business Officer

Mar 16, 2021

Prelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update

Mar 15, 2021

Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends Study to Continue with Modifications

Mar 15, 2021

Silverback Therapeutics Announces the Appointment of Dr. Maria Koehler to its Board of Directors

Mar 12, 2021

Xenon Pharmaceuticals Announces Closing of $115 Million Public Offering and Full Exercise of the Underwriters� Option to Purchase Additional Shares

Mar 11, 2021

Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Mar 11, 2021

Selecta Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

Mar 11, 2021

Sierra Oncology Reports 2020 Year End Results

Mar 11, 2021

Aerpio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Mar 10, 2021

Adicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma

Mar 10, 2021

AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19

Mar 9, 2021

Q32 Bio Appoints Dr. Jason Campagna as Chief Medical Officer

Mar 9, 2021

Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial

Mar 9, 2021

Ventyx Biosciences Raises $114 Million Financing led by venBio Partners to Advance Diverse Pipeline of Immunology Programs

Mar 8, 2021

Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate

Mar 8, 2021

CLEAVE THERAPEUTICS LICENSES FIRST-IN-CLASS VCP/P97 INHIBITOR CB-5339 TO CASI PHARMACEUTICALS FOR GREATER CHINA REGION

Mar 8, 2021

Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101 for the Treatment of Major Depressive Disorder (MDD)

Mar 8, 2021

U.S. Food and Drug Administration Grants Fast Track Designation to Three Passage Bio Gene Therapy Candidates Targeting Rare CNS Disorders

Mar 5, 2021

Compass Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Mar 5, 2021

IMARA REPORTS FULL YEAR 2020 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

Mar 4, 2021

Compass Therapeutics to Commence Trading on the OTCQB Venture Market Under the Symbol �CMPX�

Mar 4, 2021

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results

Mar 4, 2021

Graybug Vision Announces Full Year 2020 Financial Results and Recent Corporate Developments

Mar 4, 2021

NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Mar 4, 2021

Adicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors

Mar 3, 2021

BlossomHill Therapeutics Closes $71M Series A Financing

Mar 3, 2021

Passage Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Highlights

Mar 3, 2021

Wendy White Joins TigerConnect��as Chief Marketing Officer

Mar 3, 2021

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

Mar 2, 2021

Fusion Pharmaceuticals To Expand Pipeline With Acquisition Of IPN-1087, A Small Molecule Targeting NTSR1, From Ipsen

Mar 2, 2021

Janux Therapeutics Announces $56 Million Series A to Advance Novel Cancer Drug Candidates using T Cell Engager (TRACTr) Technology

Mar 2, 2021

ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China

Mar 2, 2021

Lisa Deschamps Joins Verona Pharma as Non-Executive Director

Mar 1, 2021

Xenon Pharmaceuticals Reports 2020 Financial Results and Provides Corporate Update

Mar 1, 2021

HARPOON THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 1, 2021

VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis

Mar 1, 2021

Turning Point Therapeutics Reports Fourth-Quarter and Full-Year Financial Results, Provides Operational Updates

Feb 25, 2021

Alector Reports 2020 Fourth Quarter and Full Year Financial Results and Provides Business Update

Feb 25, 2021

Tricida Announces Fourth Quarter and Full Year 2020 Financial Results

Feb 25, 2021

SpringWorks Therapeutics Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update

Feb 25, 2021

Merck to Acquire Pandion Therapeutics

Feb 25, 2021

Tricida Provides Update on FDA Interactions

Feb 24, 2021

Aeglea BioTherapeutics Appoints Sara Brownstein to Board of Directors

Feb 23, 2021

scPharmaceuticals Inc. Announces Results of Type A End-of-Review Meeting with FDA Regarding FUROSCIX® NDA

Feb 22, 2021

Valneva Initiates Phase 3 Clinical Lot Consistency Study for its Single-Shot Chikungunya Vaccine Candidate

Feb 22, 2021

Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting

Feb 22, 2021

Xtant Medical Announces $20 Million Private Placement

Feb 19, 2021

Adagio Therapeutics Announces Dosing of First Patient in Phase 1 Trial of ADG20, its Lead Monoclonal Antibody Candidate for the Treatment and Prevention of COVID-19

Feb 18, 2021

EVOX THERAPEUTICS COMPLETES £69.2 MILLION SERIES C FINANCING

Feb 17, 2021

Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Feb 17, 2021

Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock

Feb 17, 2021

Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR™ in Gene Therapy

Feb 17, 2021

scPharmaceuticals Inc. Appoints Renowned Heart Failure Specialist William T. Abraham, M.D., to its Board of Directors

Feb 16, 2021

Adicet Bio, Inc. Announces Closing of $152 Million Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Feb 16, 2021

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

Feb 16, 2021

PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board

Feb 16, 2021

Arcutis Biotherapeutics Announces Closing of Underwriters’ Over-Allotment Option in Connection with Public Offering of Common Stock

Feb 12, 2021

Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

Feb 11, 2021

Decibel Therapeutics Announces Pricing of Initial Public Offering

Feb 11, 2021

Fusion Pharmaceuticals Appoints Philina Lee, Ph.D., To Board Of Directors

Feb 10, 2021

TERNS PHARMACEUTICALS, INC. ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING AND EXERCISE IN FULL OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES

Feb 10, 2021

Synlogic Appoints Lisa Kelly-Croswell to its Board of Directors

Feb 10, 2021

Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry Age-Related Macular Degeneration (AMD) in Patients with High-Risk Genetic Variants

Feb 9, 2021

AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19

Feb 8, 2021

FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment Options

Feb 8, 2021

Gemini Therapeutics Debuts as Publicly Traded Precision Medicine Company Focused on Age-Related Macular Degeneration

Feb 4, 2021

CRINETICS PHARMACEUTICALS LEAD ACTH ANTAGONIST FOR CONGENITAL ADRENAL HYPERPLASIA AND CUSHING’S DISEASE (CRN04894)ADVANCES INTO PHASE 1 STUDY

Feb 4, 2021

Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19

Feb 3, 2021

CRINETICS PHARMACEUTICALS ADVANCES CRN04777 FOR CONGENITAL HYPERINSULINISM INTO PHASE 1 STUDY

Feb 3, 2021

VectivBio Announces First Patient Dosed in Pivotal Phase 3 Trial of Apraglutide for the Treatment of Short Bowel Syndrome

Feb 2, 2021

Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

Feb 1, 2021

Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis

Feb 1, 2021

Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy

Feb 1, 2021

Valneva Announces UK Government Exercise of Option for 40 Million Doses of its Inactivated, Adjuvanted COVID-19 Vaccine

Feb 1, 2021

VYNE Therapeutics Announces FDA Approval of AMZEEQ� (Minocycline) Label Update

Jan 28, 2021

Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations

Jan 28, 2021

Valneva Commences Manufacturing of its Inactivated, Adjuvanted COVID-19 Vaccine, Completes Phase 1/2 Study Recruitment

Jan 26, 2021

AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%

Jan 26, 2021

VYNE Therapeutics Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

Jan 25, 2021

Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income Countries

Jan 25, 2021

ASPEN NEUROSCIENCE ANNOUNCES APPOINTMENT OF DAMIEN MCDEVITT, PHD AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

Jan 25, 2021

Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s Disease

Jan 21, 2021

AbCellera-Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for Residents

Jan 21, 2021

Passage Bio Announces Pricing of Public Offering

Jan 21, 2021

VYNE Therapeutics Announces Contract Execution for AMZEEQ® (minocycline) and ZILXI® (minocycline) with Major Pharmacy Benefit Management (PBM) Company

Jan 20, 2021

OmniGuide Receives 510(k) FDA Clearance for OTO-U Otology CO2 Surgical Fiber

Jan 20, 2021

IMARA ANNOUNCES THE APPOINTMENT OF KENNETH ATTIE, M.D. AS CHIEF MEDICAL OFFICER

Jan 20, 2021

Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis

Jan 19, 2021

Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference

Jan 15, 2021

Valneva Announces Amendment to Deerfield and OrbiMed Debt Facility Terms

Jan 14, 2021

Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021

Jan 14, 2021

Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

Jan 14, 2021

Dr. Han Myint Appointed as NextCure’s Chief Medical Officer

Jan 14, 2021

Augmedix Launches Tech-Enabled Service Within Emergency Departments to Provide Real-Time Support and Optimize Clinician Workflows

Jan 14, 2021

adMare Launches Abdera with AbCellera as a Founding Partner

Jan 13, 2021

Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis

Jan 13, 2021

HARPOON THERAPEUTICS GRANTED ORPHAN DRUG DESIGNATION FROM FDA FOR HPN217 FOR TREATMENT OF MULTIPLE MYELOMA

Jan 12, 2021

Delfi Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early Detection Liquid Biopsy for Multiple Cancers

Jan 12, 2021

Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Jan 12, 2021

Valneva in Advanced Discussions with European Commission to Supply up to 60 Million Doses of Inactivated, Adjuvanted COVID-19 Vaccine Candidate

Jan 12, 2021

TERNS COMPLETES ENROLLMENT IN PHASE 2A CLINICAL TRIAL OF TERN-101 IN NASH PATIENTS 

Jan 11, 2021

Synlogic Outlines Upcoming Clinical Milestones

Jan 11, 2021

Turning Point Therapeutics Announces 2021 Milestone Targets

Jan 11, 2021

ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones

Jan 11, 2021

Turning Point and Zai Lab Broaden Collaboration

Jan 11, 2021

Matthew Moore Joins Arcutis as Chief Business Officer

Jan 11, 2021

HARPOON THERAPEUTICS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK

Jan 11, 2021

Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Jan 8, 2021

Galecto Appoints Anne Prener to its Board of Directors

Jan 7, 2021

Kala Pharmaceuticals Announces Availability of EYSUVIS� for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

Jan 7, 2021

Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Data Expected in Second Quarter 2021

Jan 7, 2021

Gemini Therapeutics Announces FDA Fast Track Designation Granted for GEM103 for the Treatment of Dry Age-Related Macular Degeneration (AMD) in Patients with Complement Factor H (CFH) Loss of Function Gene Variants

Jan 6, 2021

TigerConnect Acquires Critical Alert, Ends 2020 with Second Major Acquisition

Jan 6, 2021

IMARA REPORTS PHASE 2A CLINICAL TRIAL RESULTS OF IMR-687 IN ADULT PATIENTS WITH SICKLE CELL DISEASE

Jan 6, 2021

CRINETICS PHARMACEUTICALS?TO?REVIEW 2020 ACCOMPLISHMENTS AND PROVIDE 2021 PLANS AT 39TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Jan 6, 2021

Alpine Immune Sciences Announces Executive Leadership Addition and Promotion

Jan 5, 2021

Ikena Oncology Closes $120 Million Series B Financing Led by Omega Funds

Jan 5, 2021

TERNS APPOINTS THREE NEW INDEPENDENT DIRECTORS TO ITS BOARD

Jan 5, 2021

TERNS CLOSES $87 MILLION SERIES C FINANCING TO ADVANCE NASH PORTFOLIO

Jan 5, 2021

89bio Provides Business Outlook for 2021

Jan 5, 2021

MBX Biosciences Appoints Mary Jane Geiger, M.D., Ph.D., as Chief Medical Officer

Jan 5, 2021

TELA Bio Appoints Renowned Surgeon as Vice President of Clinical Development

Jan 5, 2021

Aerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 Trial

Jan 4, 2021

Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells

Jan 4, 2021

Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis

Jan 4, 2021

HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN328, AN ANTI-DLL3 T CELL ENGAGER FOR TREATMENT OF SMALL CELL LUNG CANCER AND OTHER DLL3-ASSOCIATED TUMORS

Jan 1, 2021

SCORPION THERAPEUTICS ANNOUNCES OVERSUBSCRIBED $162 MILLION SERIES B FINANCING

Dec 28, 2020

Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China

Dec 23, 2020

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Dec 22, 2020

Q32 Bio Appoints Experienced Biopharmaceutical Leader Mark Iwicki as Chairman of Board of Directors

Dec 21, 2020

Arcutis Biotherapeutics Added to Nasdaq Biotechnology Index

Dec 21, 2020

ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101

Dec 21, 2020

Keros Therapeutics Announces Addition to NASDAQ Biotechnology Index

Dec 17, 2020

Decibel Therapeutics Announces DB-020 Has Been Granted Fast Track Designation by the U.S. Food and Drug Administration

Dec 17, 2020

Cullinan Oncology Completes $131.2 Million Series C Financing

Dec 17, 2020

NextCure Provides Updates on NC318 Clinical Program

Dec 17, 2020

Aeglea BioTherapeutics Appoints Alison Lawton to Board of Directors

Dec 17, 2020

Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta

Dec 17, 2020

Keros Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors

Dec 16, 2020

Passage Bio Announces Gene Therapy Manufacturing Research and Development Site

Dec 16, 2020

Valneva Initiates Phase 1/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine Candidate

Dec 15, 2020

Mereo BioPharma Provides Update on AIM Delisting and Continued Listing of its ADSs on Nasdaq, and Provides Update on agreements with Silicon Valley Bank and Kreos Capital

Dec 15, 2020

Harmony Biosciences Enrolls First Patient In Phase 2 Trial Evaluating Pitolisant For Excessive Daytime Sleepiness In Patients With Prader-Willi Syndrome

Dec 15, 2020

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020

Dec 15, 2020

SpringWorks Therapeutics Announces Executive Leadership Promotions

Dec 15, 2020

Lilly Announces Agreement to Acquire Prevail Therapeutics

Dec 14, 2020

Synlogic Announces Advancement of SYNB1891 to Combination Arm Dosing with PD-L1 Checkpoint Inhibitor in the on-going Phase 1 Study for the Treatment of Solid Tumors and Lymphoma

Dec 14, 2020

X4 Pharmaceuticals Appoints Diego Cadavid, M.D., as Chief Medical Officer

Dec 14, 2020

HLS Therapeutics Reports Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with Vascepa® (Icosapent Ethyl)

Dec 14, 2020

BELLUS Health Announces First Patient Dosed in its Phase 2 BLUEPRINT Trial of BLU-5937 for the Treatment of Chronic Pruritus Associated with Atopic Dermatitis

Dec 14, 2020

VectivBio Appoints Sandip Kapadia to its Board of Directors

Dec 11, 2020

Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial

Dec 11, 2020

Galecto Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update

Dec 11, 2020

ESCAPE BIO APPOINTS EDWARD OWENS AND SCOTT MORRISON TO BOARD OF DIRECTORS

Dec 11, 2020

Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN Mutations

Dec 11, 2020

Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors

Dec 10, 2020

Acutus Medical Announces CE Mark and European Launch of AcQCross™ Transseptal System, a Fully Integrated Family of Transseptal Crossing Products

Dec 10, 2020

X4 Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Mavorixafor for the Treatment of WHIM Syndrome

Dec 10, 2020

Fusion Pharmaceuticals Initiates Multi-Dose Portion Of Phase 1 Trial Of FPI-1434 In Patients With Advanced Solid Tumors

Dec 10, 2020

Passage Bio Receives MHRA Clinical Trial Authorization for PBGM01 for Treatment of GM1 Gangliosidosis

Dec 10, 2020

AbCellera Announces Pricing of Initial Public Offering

Dec 9, 2020

Arcutis Highlights Advanced Pipeline & Unique Immuno-Dermatology Drug Development Capabilities at Virtual Investor Day on December 9, 2020

Dec 9, 2020

Synlogic Appoints Michael Heffernan to its Board of Directors

Dec 8, 2020

Sonendo® Reaches 500,000 Patients Treated Milestone with the GentleWave® Procedure

Dec 8, 2020

HARPOON THERAPEUTICS REPORTS CLINICAL PROGRESS ACROSS ALL FOUR TRITAC® PIPELINE DEVELOPMENT PROGRAMS

Dec 8, 2020

BELLUS Health Announces First Patient Dosed in its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough

Dec 8, 2020

Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer Who Have Not Been Treated with a ROS1 Tyrosine Kinase Inhibitor

Dec 8, 2020

RayzeBio Completes $105M Series B Financing to Advance Targeted Radiopharmaceuticals for Cancer

Dec 8, 2020

Tricida Announces Updates on Veverimer Development Program, Regulatory Status and New Patent Extending Protection through 2038

Dec 8, 2020

Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program

Dec 8, 2020

Silverback Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters� Option to Purchase Additional Shares

Dec 7, 2020

IMARA PRESENTS IMR-687 PHASE 2A OPEN LABEL EXTENSION CASE REPORTS ON TWO PATIENTS WITH SICKLE CELL DISEASE AT THE 62ND ASH ANNUAL MEETING AND EXPOSITION

Dec 7, 2020

Acutus Medical Launches AcQBlate® Force Sensing Ablation System in Europe

Dec 7, 2020

Synlogic Presents SYNB8802 for Enteric Hyperoxaluria at the American Institute of Chemical Engineers Conference on Microbiome Engineering

Dec 7, 2020

Passage Bio Teams with Catalent to Start CGMP Manufacturing for Lead Gene Therapy Products

Dec 7, 2020

BELLUS Health Appoints Ramzi Benamar as Chief Financial Officer

Dec 7, 2020

scPharmaceuticals Inc. Receives Complete Response Letter from FDA for FUROSCIX�

Dec 7, 2020

Sierra Oncology Announces Momelotinib Data for Intermediate / High-risk Myelofibrosis Patients with Lower Baseline Platelet Counts

Dec 7, 2020

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050 Preclinical Data, at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition

Dec 7, 2020

Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters� Option to Purchase Additional Shares

Dec 7, 2020

Arcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis

Dec 7, 2020

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at AES2020, the Virtual Annual Meeting of the American Epilepsy Society

Dec 6, 2020

Corvus Presents New Data on its Investigational ITK Inhibitor CPI-818 at the American Society of Hematology (ASH) Annual Meeting & Exposition

Dec 6, 2020

CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Potential Benefit in Preventing Acute GVHD at the 62nd American Society of Hematology Meeting

Dec 5, 2020

Sierra Oncology Presents Long-term Overall Survival and Sustained Efficacy Outcomes Data for Momelotinib at ASH Annual Meeting

Dec 3, 2020

Pandion Therapeutics Appoints Katina Dorton to its Board of Directors

Dec 2, 2020

Valneva Announces Acceleration of Pediatric Development for Lyme Disease Vaccine Candidate

Dec 1, 2020

Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria

Dec 1, 2020

Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of Directors

Dec 1, 2020

Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis

Nov 30, 2020

CTI BioPharma Announces Publication of Article Highlighting Pacritinib Data from the PAC203 Phase 2 Study in Myelofibrosis in Blood Advances

Nov 30, 2020

Galecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results in European Respiratory Journal, Showing Marked Impact on Several IPF Biomarkers

Nov 30, 2020

Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal Dementia

Nov 28, 2020

BHV3000-310 FPFV PRESS RELEASE DRAFT FOR REVIEW

Nov 23, 2020

Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley Bank

Nov 23, 2020

Mereo BioPharma Appoints Suba Krishnan, M.D. Senior Vice President of Clinical Development

Nov 23, 2020

Arcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp and Body Psoriasis

Nov 23, 2020

PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53

Nov 23, 2020

Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors

Nov 20, 2020

AbCellera-Discovered Antibody Granted Interim Authorization by Health Canada as a Treatment for COVID-19

Nov 19, 2020

Peter Thiel Joins AbCellera�s Board of Directors

Nov 19, 2020

Ikena Oncology Assembles Multi-Disciplinary Scientific Advisory Board

Nov 19, 2020

AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic Acidemia

Nov 18, 2020

AbCellera Expands Technology Stack with Acquisition of Trianni for $90 Million

Nov 18, 2020

Adagio Therapeutics COVID-19 Antibody Demonstrates Best-in-Class Breadth and Potency Against a Range of Coronaviruses that Pose Human Threat

Nov 18, 2020

Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001

Nov 18, 2020

Pionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314

Nov 17, 2020

Verrica Pharmaceuticals Announces Receipt of Final FDA Minutes Following Type A Meeting Regarding Resubmission of the NDA for VP-102 in Molluscum

Nov 17, 2020

Keros Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Nov 17, 2020

ORIC Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Nov 17, 2020

HLS Therapeutics Announces Health Canada Approval of PERSERIS� for the Treatment of Schizophrenia

Nov 17, 2020

Augmedix Announces Third Quarter Results

Nov 17, 2020

IMARA ANNOUNCES THE APPOINTMENT OF LYNETTE HOPKINSON AS SENIOR VICE PRESIDENT OF REGULATORY

Nov 16, 2020

scPharmaceuticals Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update

Nov 16, 2020

Kala Pharmaceuticals Provides Update on Launch Plans for EYSUVIS™ for the Treatment of Dry Eye Disease

Nov 16, 2020

Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

Nov 16, 2020

CRINETICS PHARMACEUTICALS APPOINTS ACROMEGALY EXPERT, PETER TRAINER, VICE PRESIDENT OF CLINICAL ENDOCRINOLOGY

Nov 13, 2020

Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

Nov 13, 2020

89bio Presents Updated Clinical Data from Positive Phase 1b/2a Study of BIO89-100 in NASH at AASLD’s The Liver Meeting® 2020

Nov 13, 2020

NextCure Reports Third Quarter 2020 Financial Results

Nov 13, 2020

Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Study

Nov 13, 2020

PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights

Nov 12, 2020

Acutus Medical Reports Third Quarter 2020 Results

Nov 12, 2020

Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Recent Corporate Developments

Nov 12, 2020

Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates

Nov 12, 2020

BELLUS Health Reports Third Quarter 2020 Financial Results and Business Highlights

Nov 12, 2020

Steven Mickelsen, MD, Joins Acutus Medical as Chief Translational Science Officer

Nov 12, 2020

Alpine Immune Sciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Nov 12, 2020

HARPOON THERAPEUTICS PRESENTS ENCOURAGING PRECLINICAL DATA FOR HPN601 EPCAM PROTRITAC™ PROGRAM AT 35TH SITC ANNUAL MEETING

Nov 12, 2020

SpringWorks Therapeutics Reports Third Quarter 2020 Financial Results and Recent Business Highlights

Nov 11, 2020

TELA Bio Announces Third Quarter 2020 Financial Results

Nov 11, 2020

Passage Bio Highlights University of Pennsylvania’s Gene Therapy Program’s Newly Published Research to Prevent Toxicity Associated with Gene Therapy

Nov 11, 2020

Edgewise Therapeutics Initiates Phase 1 Clinical Trial of EDG-5506 in Becker Muscular Dystrophy

Nov 10, 2020

Verrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts (CARE-1)

Nov 10, 2020

CTI BioPharma Reports Third Quarter 2020 Financial Results

Nov 10, 2020

Prelude Therapeutics Announces Third Quarter 2020 Financial Results

Nov 10, 2020

Fusion Pharmaceuticals Announces Third Quarter 2020 Financial Results And Business Update

Nov 10, 2020

89bio Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Nov 10, 2020

Alector Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Nov 10, 2020

Adagio Therapeutics Raises $80M Series B Round to Further Advance Best-In-Class Antibodies for Coronavirus Treatment and Prevention

Nov 10, 2020

Aerpio Reports Third Quarter 2020 Financial Results and Provides Business Update

Nov 10, 2020

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results

Nov 10, 2020

Passage Bio Reports Third Quarter 2020 Financial Results and Recent Business Highlights

Nov 9, 2020

Verrica Pharmaceuticals Reports Third Quarter 2020 Financial Results

Nov 9, 2020

Tricida Announces Third Quarter 2020 Financial Results

Nov 9, 2020

AbCellera-Discovered Antibody Receives U.S. FDA Emergency Use Authorization as a Monotherapy for the Treatment of COVID-19

Nov 9, 2020

Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1

Nov 9, 2020

Corvus Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 6, 2020

CRINETICS PHARMACEUTICALS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Nov 5, 2020

Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Nov 5, 2020

Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights

Nov 5, 2020

Selecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

Nov 5, 2020

X4 Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Nov 5, 2020

ORIC Pharmaceuticals Reports Third Quarter 2020 Financial and Operational Update

Nov 5, 2020

Adicet Reports Third Quarter 2020 Financial Results and Provides Business Update

Nov 5, 2020

IMARA REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

Nov 5, 2020

Arcutis Announces Third Quarter 2020 Financial Results and Provides Business Update

Nov 5, 2020

Sierra Oncology Reports Third Quarter 2020 Results

Nov 5, 2020

Xenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Nov 5, 2020

Merck to Acquire VelosBio

Nov 5, 2020

Synlogic Reports Third Quarter 2020 Financial Results and Provides Business Update

Nov 4, 2020

VectivBio Strengthens Business Development Capabilities with Key Appointments

Nov 4, 2020

HARPOON THERAPEUTICS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Nov 4, 2020

Arcutis Announces Appointment of Terrie Curran to Board of Directors

Nov 4, 2020

Synlogic Initiates Phase 1 Study of SYNB8802 for the Treatment of Enteric Hyperoxaluria

Nov 3, 2020

HARPOON THERAPEUTICS APPOINTS OMER SIDDIQUI AS VP DEVELOPMENT OPERATIONS AND PROJECT MANAGEMENT

Nov 2, 2020

Alector Provides Update on Arbitration Proceedings with Dr. Asa Abeliovich

Nov 2, 2020

Arcutis Biotherapeutics Presents New Positive Data from Phase 2 Studies of ARQ-151 (Topical Roflumilast Cream) in Chronic Plaque Psoriasis and Atopic Dermatitis

Nov 2, 2020

Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO

Nov 2, 2020

Fusion Pharmaceuticals Announces Collaboration With AstraZeneca To Develop And Commercialize Next-Generation Radiopharmaceuticals And Combination Therapies

Nov 2, 2020

Fusion Pharmaceuticals Appoints Barbara Duncan As Chairperson Of The Board Of Directors

Nov 2, 2020

X4 Pharmaceuticals Appoints Art Taveras, Ph.D., as Chief Scientific Officer

Oct 29, 2020

AbCellera and Kodiak Sciences Enter Second Antibody Discovery Collaboration for Ophthalmology Targets

Oct 29, 2020

Edgewise Therapeutics Appoints John Moore as General Counsel

Oct 29, 2020

Tricida Provides Update on FDA Interactions

Oct 29, 2020

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results

Oct 29, 2020

Turning Point Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

Oct 29, 2020

Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020

Oct 28, 2020

Passage Bio’s PBKR03 Receives Orphan Drug and Rare Pediatric Disease Designations from FDA for Treatment of Krabbe Disease

Oct 28, 2020

GentiBio Expands Leadership Team and Partnership with MIGAL to Help Advance Development of Engineered Regulatory T Cell Therapies

Oct 28, 2020

Galecto Announces Pricing of Initial Public Offering

Oct 27, 2020

Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gaucher Disease

Oct 27, 2020

Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease

Oct 27, 2020

MBX Biosciences Appoints James Cornelius to its Board of Directors

Oct 26, 2020

Jazz Pharmaceuticals Acquires SpringWorks Therapeutics’ FAAH Inhibitor Program

Oct 26, 2020

Aerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19

Oct 26, 2020

ESSA PHARMA INC. ANNOUNCES DELISTING FROM THE TSX-V

Oct 26, 2020

CRINETICS PHARMACEUTICALS ANNOUNCES PHASE 2 ACROBAT EDGE STUDY WITH PALTUSOTINE IN ACROMEGALY MET PRIMARY ENDPOINT

Oct 26, 2020

Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria

Oct 26, 2020

Passage Bio’s PBGM01 Receives Orphan Drug Designation from EMA for Treatment of GM1 Gangliosidosis

Oct 26, 2020

Arcutis Completes Enrollment in Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema

Oct 26, 2020

Adicet Appoints Don Healey, Ph.D., as Chief Technology Officer

Oct 24, 2020

Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium

Oct 22, 2020

Edgewise Therapeutics Appoints Behrad Derakhshan as Chief Business Officer

Oct 22, 2020

BELLUS Health Closes US$40 Million Public Offering of Common Shares in Canada and the United States, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Oct 22, 2020

Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell non-Hodgkin’s lymphoma

Oct 20, 2020

Selecta Biosciences and AskBio Receive FDA Rare Pediatric Disease Designation for their Gene Therapy for Methylmalonic Acidemia

Oct 20, 2020

Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs

Oct 20, 2020

Valneva Announces Positive Initial Results for Second Phase 2 Study of Lyme Disease Vaccine Candidate VLA15

Oct 20, 2020

Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS)

Oct 19, 2020

Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)

Oct 19, 2020

ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program

Oct 19, 2020

VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors

Oct 16, 2020

Edgewise Therapeutics Appoints Michael Carruthers as Chief Financial Officer

Oct 16, 2020

Valneva�s Chikungunya Vaccine Candidate Awarded EMA Prime Designation

Oct 16, 2020

IMARA ANNOUNCES FIRST PATIENT DOSED IN FORTE PHASE 2B CLINICAL TRIAL OF IMR-687 IN BETA-THALASSEMIA

Oct 15, 2020

VectivBio Closes $110 Million Crossover Financing to Advance Transformational Medicines for Rare Diseases

Oct 15, 2020

Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular Degeneration

Oct 13, 2020

Nabriva’s XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)

Oct 13, 2020

SpringWorks Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 13, 2020

CTI BioPharma Initiates Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia

Oct 13, 2020

Passage Bio Announces Publication of Preclinical Data That Show Single Injection of Optimized AAV Vector into Cerebral Spinal Fluid Corrects Neurological Disease, Supporting Advancement of PBGM01 into Clinic

Oct 13, 2020

Harmony Biosciences Receives FDA Approval For Expanded Use Of Wakix� (pitolisant) For The Treatment Of Cataplexy In Adult Patients With Narcolepsy

Oct 13, 2020

PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation

Oct 8, 2020

TigerConnect Closes $45M Series D To Meet Soaring Demand

Oct 8, 2020

X4 Pharmaceuticals Announces Fast Track Designation Granted by the FDA to Mavorixafor for the Treatment of WHIM Syndrome

Oct 8, 2020

Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in Combination with IGAN’s IgA Protease for the Treatment of IgA Nephropathy

Oct 8, 2020

Xenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-DEE Before Year-End

Oct 8, 2020

scPharmaceuticals Provides Business Update

Oct 8, 2020

Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy

Oct 7, 2020

VYNE Therapeutics Announces Covered Status for ZILXI� (minocycline) with Express Scripts

Oct 6, 2020

Arcutis Biotherapeutics Announces Closing of Public Offering and Concurrent Private Placement of Common Stock

Oct 6, 2020

Augmedix Closes $25 Million Private Placement

Oct 5, 2020

SpringWorks Therapeutics Announces Clinical Collaboration with Pfizer Inc. to Evaluate Nirogacestat in Combination with PF?06863135 in Patients with Relapsed or Refractory Multiple Myeloma

Oct 5, 2020

Corvus Pharmaceuticals Announces Co-Founding of Angel Pharmaceuticals in China

Oct 5, 2020

New Data from Corvus Phase 1 Study of CPI-006 Continues to Support its Potential as a Treatment for COVID-19

Oct 1, 2020

Xtant Medical Announces Closing of Debt Restructuring

Oct 1, 2020

VYNE Therapeutics Announces ZILXI� (minocycline) topical foam, 1.5% is Available in Pharmacies Nationwide Today, October 1st

Oct 1, 2020

X4 Pharmaceuticals Expands Board of Directors Through Appointment of Biopharmaceutical Industry Veteran Alison Lawton

Sep 30, 2020

HLS Therapeutics Acquires Portfolio of Four Royalty Interests

Sep 30, 2020

Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Supporting the Potential for Important Clinical Improvement in Patients with Chronic Refractory Gout

Sep 29, 2020

Fusion Pharmaceuticals Appoints Maria Stahl As Chief Legal Officer

Sep 29, 2020

Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis

Sep 28, 2020

BIOSHIN, BIOHAVEN'S ASIA-PACIFIC SUBSIDIARY, RAISES $60M IN SERIES A FUNDING TO ADVANCE NEUROSCIENCE PIPELINE IN ASIA-PACIFIC REGION

Sep 28, 2020

Mereo BioPharma Announces Changes to Board of Directors

Sep 28, 2020

Ascendis Pharma A/S Announces Preliminary Six-Month Data from Open-Label Extension of Phase 2 PaTH Forward Trial and Files IND Amendment to Initiate Phase 3 PaTHway Trial of TransCon™ PTH in Adult Hypoparathyroidism

Sep 25, 2020

Graybug Appoints Three New Members to its Board of Directors

Sep 25, 2020

TELA Bio Presents Additional Data from BRAVO Study of OviTex® for Ventral Hernia Repair

Sep 25, 2020

Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline

Sep 24, 2020

Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta

Sep 24, 2020

Graybug Vision Announces Pricing of Upsized Initial Public Offering

Sep 24, 2020

PMV Pharma Announces Pricing of Initial Public Offering

Sep 24, 2020

AbCellera and IGM Biosciences Announce Multi-Year Antibody Discovery Collaboration

Sep 23, 2020

Ascendis Pharma A/S Announces Filing of the Clinical Trial Notification for Phase 3 Clinical Trial of TransCon™ hGH for Pediatric Growth Hormone Deficiency in Japan

Sep 23, 2020

Silverback Therapeutics Raises $85 Million in Series C Financing; Company Announces Executive Promotions

Sep 23, 2020

Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD

Sep 23, 2020

AMA Dermatology Publishes Results from Verrica’s Two Pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients) Trials

Sep 23, 2020

First Patient Randomized in the Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory Gout

Sep 21, 2020

Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma

Sep 21, 2020

Intended Delisting and Cancellation of Ordinary Shares from Trading on AIM

Sep 21, 2020

CRINETICS PHARMACEUTICALS RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM FDA FOR CRN04777 FOR THE TREATMENT OF CONGENITAL HYPERINSULINISM

Sep 18, 2020

SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma

Sep 17, 2020

ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020

Sep 17, 2020

Acutus Medical Announces FDA Clearance of Second-Generation AcQMap 3D Imaging & Mapping Catheter

Sep 17, 2020

Passage Bio Announces Publication of Preclinical Gene Therapy Study Data from Frontotemporal Dementia Program

Sep 17, 2020

Acutus Medical Reports Second Quarter 2020 Financial Results

Sep 17, 2020

New Data from Ciforadenant Phase 1b/2 Clinical Study Presented at ESMO Virtual Congress 2020

Sep 16, 2020

Arcutis Completes Enrollment in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis

Sep 16, 2020

89bio Announces Pricing of Upsized Public Offering of Common Stock

Sep 16, 2020

Interim Data Reported for AbCellera-Discovered COVID-19 Antibody in Phase 2 Clinical Trials

Sep 16, 2020

Verona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease

Sep 16, 2020

SpringWorks Therapeutics Announces Collaboration with Children’s Oncology Group to Conduct a Phase 2 Clinical Trial of Nirogacestat in Pediatric Patients with Desmoid Tumors and Reports Publication of Nirogacestat Case Series in Pediatric/Young Adult Desmoid Tumor Patients

Sep 16, 2020

Adicet Bio Appoints Nick Harvey as Chief Financial Officer

Sep 15, 2020

Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma Trial

Sep 15, 2020

VectivBio Appoints Nader N. Youssef, M.D., as Senior Vice President, Head of Global Clinical Development and Medical Affairs

Sep 15, 2020

Compass Therapeutics, Inc. Provides Corporate Update

Sep 15, 2020

Galecto’s Oral Galectin-3 Inhibitor GB1211 Well Tolerated in Phase I Clinical Data Presented Recently at Several Scientific Conferences

Sep 15, 2020

Adicet Announces Completion of Merger with resTORbio

Sep 14, 2020

ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Sep 14, 2020

Synlogic Appoints David Hava, Ph.D., as Chief Scientific Officer

Sep 14, 2020

NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors

Sep 14, 2020

SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma

Sep 14, 2020

Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government

Sep 14, 2020

89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH

Sep 14, 2020

ESCAPE BIO CLOSES $73 MILLION IN CROSSOVER FINANCING TO ADVANCE CLINICAL DEVELOPMENT OF PRECISION NEUROLOGY MEDICINES FOR GENETIC NEURODEGENERATION – ESCAPE BIO

Sep 11, 2020

Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting

Sep 11, 2020

Corvus Pharmaceuticals Appoints Edith Mitchell, M.D., to Board of Directors

Sep 10, 2020

Prevail Therapeutics Announces Appointment of William H. Carson, M.D., to Board of Directors

Sep 10, 2020

Gemini Therapeutics Enrolls First Patient in Phase 2a Study of GEM103 for Dry Age-related Macular Degeneration

Sep 10, 2020

Corvus Pharmaceuticals Provides Update on Clinical Trial of CPI-006 for Patients with COVID-19

Sep 10, 2020

Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services

Sep 9, 2020

Valneva Announces New IXIARO® Supply Contract with the US Government worth up to $166 million

Sep 9, 2020

Adagio Therapeutics Strengthens Management Team with Appointments of Eric Kimble as Chief Commercial Officer and Ed Campanaro as SVP of Clinical Operations

Sep 9, 2020

Cleave Therapeutics Announces Preclinical Research Collaboration with Jazz Pharmaceuticals in Acute Myeloid Leukemia (AML)

Sep 9, 2020

Kinnate Biopharma Appoints Dean J. Mitchell as Chairman of the Board

Sep 8, 2020

Ascendis Pharma A/S Submits Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon™ hGH for Treatment of Pediatric Growth Hormone Deficiency

Sep 8, 2020

BELLUS Health Announces Design for its Phase 2b Trial with BLU-5937 in Refractory Chronic Cough

Sep 8, 2020

PMV Pharma Appoints Laurie Stelzer to the Board of Directors and Robert Ticktin as General Counsel

Sep 8, 2020

Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics

Sep 8, 2020

Arcutis Biotherapeutics to Accelerate ARQ-151 (Topical Roflumilast Cream) into Phase 3 Trials for the Treatment of Atopic Dermatitis Following End-of-Phase 2 Meeting with FDA

Sep 8, 2020

Acutus Medical Announces Pulsed Field Ablation Program and Initial Pre-Clinical Results

Sep 8, 2020

Valneva Initiates Phase 3 Clinical Study for its Chikungunya Vaccine Candidate VLA1553

Sep 8, 2020

Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

Sep 8, 2020

VelosBio Appoints Paul Bavier as General Counsel

Sep 4, 2020

Ascendis Pharma A/S Announces U.S. Food and Drug Administration (FDA) Accepts Biologics License Application (BLA) for TransCon™ hGH for Pediatric Growth Hormone Deficiency (GHD)

Sep 4, 2020

CRINETICS PHARMACEUTICALS PROVIDES NEW DATA FROM PALTUSOTINE AND ACTH ANTAGONIST DEVELOPMENT PROGRAMS AT EUROPEAN CONGRESS OF ENDOCRINOLOGY

Sep 4, 2020

Graybug Vision Appoints Robert Breuil as Chief Financial Officer

Sep 3, 2020

89bio Initiates Phase 2 Trial of BIO89-100 in Patients with Severe Hypertriglyceridemia

Sep 3, 2020

CRINETICS PHARMACEUTICALS APPOINTS RARE DISEASE EXECUTIVE, CAMILLE L. BEDROSIAN, M.D., TO BOARD OF DIRECTORS

Sep 3, 2020

ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement Priced At-The-Market of Common Shares and 15-Month Purchase Warrants for Potential Additional Gross Proceeds of $23.9 Million

Sep 2, 2020

X4 Pharmaceuticals Announces Publication of Mavorixafor Phase 2 Clinical Data for Treatment of WHIM Syndrome in ‘Blood’ - the Official Journal of the American Society of Hematology

Sep 1, 2020

TigerConnect Acquires Call Scheduler, Launches Fully-Integrated TigerSchedule™ to Simplify Physician On-Call Scheduling

Sep 1, 2020

Selecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Valley Bank

Sep 1, 2020

Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 Patients

Aug 31, 2020

Pandion Reports Second Quarter 2020 Financial Results and Provides Business Update

Aug 31, 2020

Turning Point Therapeutics Announces Scientific Advisory Board

Aug 31, 2020

VelosBio Announces FDA Fast Track and Orphan Drug Designations for VLS-101 in Patients with Mantle Cell Lymphoma

Aug 31, 2020

NeuroPace Raises $67 Million Financing to Support Commercial Expansion of the RNS® System for Refractory Epilepsy

Aug 27, 2020

Galecto, Inc. Receives U.S. and EU Orphan Drug Designations for GB0139 in Idiopathic Pulmonary Fibrosis

Aug 27, 2020

Gemini Therapeutics Appoints Dr. Tuyen Ong as Independent Director

Aug 26, 2020

Kinnate Biopharma Closes $98 Million Series C Financing

Aug 26, 2020

Harpoon Therapeutics Names Karin Ann Thacker, M.Sc., VP Regulatory Affairs and Quality Assurance

Aug 26, 2020

Silverback Therapeutics Initiates Phase 1 Clinical Study of SBT6050

Aug 25, 2020

ReViral Raises $44 Million in Series C Financing

Aug 25, 2020

Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease

Aug 25, 2020

Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease

Aug 24, 2020

Compass Therapeutics Announces Publication in the Journal Science of Preclinical Data Supporting the Potential of CTX-2026, a Novel Antibody to the Butyrophilin BTN3A1, in Ovarian Cancer Tumor Models

Aug 24, 2020

Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors

Aug 24, 2020

Prelude Therapeutics Announces Closing of $50M Series C Financing

Aug 24, 2020

Tricida Receives Complete Response Letter from the FDA for its New Drug Application for Veverimer for the Treatment of Metabolic Acidosis and Slowing of Kidney Disease Progression in Patients with Metabolic Acidosis Associated with CKD

Aug 24, 2020

Xtant Medical Announces U.S. Commercial Launch of the Matriform� Si for Spinal Fusion Procedures

Aug 21, 2020

Harmony Biosciences Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares

Aug 20, 2020

AbCellera Acquires OrthoMab Bispecific Platform to Propel the Development of Antibody Therapies for Pharma and Biotech Partners

Aug 19, 2020

Turning Point Therapeutics Reports Early Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib, Provides Regulatory Update

Aug 19, 2020

Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD

Aug 18, 2020

Ikena Oncology Appoints Dr. Sergio Santillana, MD, MSc, MBA as Chief Medical Officer

Aug 17, 2020

Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial Officer

Aug 17, 2020

Aerin Medical Announces Appointment of Matt Brokaw as President and CEO and Closing of $48MM Equity Financing

Aug 14, 2020

Imara Reports Second Quarter 2020 Financial Results and Business Highlights

Aug 14, 2020

Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020

Aug 13, 2020

Passage Bio Reports Second Quarter 2020 Financial Results and Recent Business Highlights

Aug 13, 2020

scPharmaceuticals Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update

Aug 13, 2020

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results

Aug 13, 2020

Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease

Aug 13, 2020

BELLUS Health Reports Second Quarter 2020 Financial Results and Business Highlights

Aug 13, 2020

89bio Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Aug 12, 2020

TELA Bio Announces Second Quarter 2020 Financial Results

Aug 12, 2020

SpringWorks Therapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights

Aug 12, 2020

Aerpio Reports Second Quarter 2020 Financial Results and Provides Business Update

Aug 12, 2020

Ascendis Pharma A/S Receives Orphan Designation for TransCon™ CNP for the Treatment of Achondroplasia in Europe

Aug 12, 2020

Ikena Oncology Announces Publication in Nature Communications of Preclinical Data Supporting the Therapeutic Potential of AHR Blockade

Aug 11, 2020

Alpine Immune Sciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Aug 11, 2020

Prevail Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights

Aug 11, 2020

Fusion Pharmaceuticals Announces Second Quarter 2020 Financial Results And Business Update

Aug 11, 2020

Arcutis Announces Second Quarter 2020 Financial Results and Provides Business Update

Aug 11, 2020

Alector Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Aug 11, 2020

KaNDY Therapeutics to be acquired by Bayer AG for up to $1.5 billion

Aug 11, 2020

Verrica Pharmaceuticals Licenses LTX-315, A First-in-Class Oncolytic Peptide Based Immunotherapy, from Lytix Biopharma AS, for the Treatment of Dermatologic Oncology Indications

Aug 11, 2020

Press Release: Bayer to Acquire UK-Based KaNDy Therapeutics

Aug 10, 2020

Acutus Medical Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Aug 10, 2020

Terns Appoints Senthil Sundaram as Chief Executive Officer, Mark Vignola, PhD, as Chief Financial Officer, and Erink Quirk, M.D. as President

Aug 10, 2020

Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates

Aug 10, 2020

Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights

Aug 10, 2020

Keros Therapeutics to be Featured on The Balancing Act's """"Behind the Mystery"""" Rare Disease Series

Aug 7, 2020

Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Aug 6, 2020

CTI BioPharma Reports Second Quarter 2020 Financial Results

Aug 6, 2020

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020

Aug 6, 2020

Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Aug 6, 2020

Sierra Oncology Reports Second Quarter 2020 Results

Aug 6, 2020

Nabriva Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates

Aug 6, 2020

Synlogic Reports Second Quarter 2020 Financial Results and Provides Business Update

Aug 6, 2020

Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Aug 6, 2020

Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Updates

Aug 6, 2020

ObsEva Announces Second Quarter 2020 Financial Results and Business Update

Aug 6, 2020

Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib

Aug 6, 2020

Glaukos Corporation Announces Second Quarter 2020 Financial Results

Aug 6, 2020

NextCure Reports Second Quarter 2020 Financial Results

Aug 5, 2020

Tricida Announces Second Quarter 2020 Financial Results

Aug 5, 2020

Verrica Pharmaceuticals Reports Second Quarter 2020 Financial Results

Aug 5, 2020

Harpoon Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Aug 5, 2020

ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Update

Aug 5, 2020

ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics

Aug 5, 2020

GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimmune and Inflammatory Diseases

Aug 5, 2020

Adicet Bio Receives $10 Million Product Development Milestone From Regeneron

Aug 5, 2020

Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan

Aug 5, 2020

Acutus Medical Announces Pricing of Initial Public Offering

Aug 4, 2020

Bethany Dudek Joins Arcutis as Vice President of Quality

Aug 4, 2020

Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for the Prevention and Treatment of ARDS in Patients with Moderate to Severe COVID-19

Aug 4, 2020

Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program Update

Aug 4, 2020

ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection

Aug 3, 2020

PMV Pharma Closes $70 Million in Series D Financing

Aug 3, 2020

VelosBio Appoints Dr. Enoch Kariuki as Chief Financial Officer

Aug 3, 2020

Selecta Biosciences Appoints Peter G. Traber, MD as Chief Medical Officer

Aug 3, 2020

Dr. Rich Heyman appointed as Chair of the Board of Directors of PMV Pharma

Aug 3, 2020

The Journal of Drugs in Dermatology Publishes Results from Positive Phase 1/2a Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis

Aug 3, 2020

Graybug Vision Appoints Leading Ophthalmologists and Retinal Experts to Join Its Scientific Advisory Board

Aug 3, 2020

AbCellera Provides COVID-19 Program Update with the Start of Phase 3 Clinical Trials and the Expansion of its COVID-19 Antibody Database

Aug 3, 2020

Aspen Neuroscience Announces Management Transition

Jul 31, 2020

Preliminary Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis

Jul 31, 2020

Stereotaxis and Acutus Medical Announce First Integrated Cardiac Ablation Procedure with TeleRobotic Support

Jul 30, 2020

resTORbio Provides Corporate Update and Reports Second Quarter 2020 Financial Results

Jul 30, 2020

Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia

Jul 30, 2020

Synlogic Announces Promotion of Antoine 'Tony' Awad to Chief Operating Officer and Additions to Leadership Team

Jul 30, 2020

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results

Jul 30, 2020

X4 Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Jul 30, 2020

Terns Announces Completion and Positive Results From Phase 1 Clinical Trial of TERN-201, A SSAO Inhibitor in Development for NASH

Jul 29, 2020

Imara Added to Membership of U.S. Small-Cap Russell 2000® Index

Jul 28, 2020

Cleave Therapeutics Announces Commencement of Phase 1 Clinical Study of CB-5339, A Valosin-Containing Protein (VCP)/p97 Inhibitor, in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Jul 28, 2020

ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000

Jul 28, 2020

resTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older Adults

Jul 28, 2020

ESSA Pharma Announces Proposed Public Offering of Common Shares

Jul 28, 2020

Alector Announces Promising Preliminary Data from AL001 Phase 1b and Phase 2 Open-Label Long-Term Dosing Study of People with Frontotemporal Dementia

Jul 28, 2020

Terns and Hanson Pharma Announce Collaboration and License Agreement for TNR-000632 in Greater China

Jul 28, 2020

Sierra Oncology Appoints Christina Thomson as General Counsel

Jul 28, 2020

NABRIVA Receives European Approval for XENLETA® (lefamulin) for Treatment of Community-Acquired Pneumonia (CAP)

Jul 28, 2020

Sobi and Selecta announce closing of previously announced strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout

Jul 27, 2020

New Published Data Show NeuroPace’s RNS® System Provides Patients with Unprecedented Seizure Reduction and Improved Quality of Life

Jul 27, 2020

MBX Biosciences Closes $34.6 Million Series A Financing in Rare Endocrine Diseases

Jul 22, 2020

SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors

Jul 22, 2020

Valneva Announces Positive Initial Results for Phase 2 Study of Lyme Disease Vaccine Candidate

Jul 22, 2020

Closing of Financing, Issued Share Capital and Total Voting Rights

Jul 22, 2020

Scientific Summary: Cyrus NextGen Antibody structure prediction beats Schrodinger and others in a large independent benchmark

Jul 21, 2020

New Cyrus “NextGen” antibody software outperforms the competition in third party test with BIOCAD biotechnology

Jul 21, 2020

AbCellera Announces Agreement with Alloy Therapeutics to Integrate Access to ATX-Gx™ Humanized Mice Platform for Antibody Discovery Programs

Jul 20, 2020

HLS Therapeutics welcomes both CADTH's recommendation to reimburse Vascepa® (icosapent ethyl) for patients with established cardiovascular disease and PMPRB's notification on its introductory price

Jul 20, 2020

Valneva Confirms Participation in UK Government COVID-19 Vaccine Response Program

Jul 20, 2020

Arcutis Enrolls Last Patient in Phase 2b Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp Psoriasis

Jul 16, 2020

XENLETA® (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia

Jul 16, 2020

Adimab Spins Out Adagio Therapeutics to Develop Broadly Protective Coronavirus Antibodies

Jul 15, 2020

The New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis

Jul 15, 2020

Tricida Provides Regulatory Update on Veverimer

Jul 15, 2020

Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S.

Jul 15, 2020

ObsEva SA Awarded Clinical Science Award for Oral Presentation at ESHRE Virtual 36th Annual Meeting, July 2020

Jul 15, 2020

ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer

Jul 14, 2020

Verrica Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Jul 13, 2020

Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema

Jul 13, 2020

NextCure Provides an Interim Update of the Phase 2 Portion of the NC318 Monotherapy Phase 1/2 Trial and Announces Departure of Chief Medical Officer

Jul 13, 2020

Turning Point Therapeutics Names Andrew Partridge As Executive Vice President and Chief Commercial Officer

Jul 13, 2020

89bio Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Jul 13, 2020

Use of Cyrus Bench cited in review article of human diseases caused by formin INF2 mutations

Jul 10, 2020

scPharmaceuticals Appoints Sara Bonstein to Board of Directors

Jul 9, 2020

TELA Bio Announces Interim Analysis from BRAVO Study of OviTex® for Ventral Hernia Repair

Jul 9, 2020

Inspire Medical Systems, Inc. Announces Appointment of Veteran Consumer Marketing Executive Georgia Garinois-Melenikiotou to its Board of Directors

Jul 8, 2020

Edgewise Therapeutics Appoints Abby H. Bronson, M.B.A., as Vice President, Patient Advocacy and External Innovation

Jul 8, 2020

CRINETICS PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FOR PALTUSOTINE FOR THE TREATMENT OF ACROMEGALY

Jul 8, 2020

VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology

Jul 8, 2020

KLAS Rates TigerConnect Among Top Advanced Clinical Communication Platforms

Jul 8, 2020

Kinnate Biopharma Appoints Dr. Richard Williams as Chief Medical Officer

Jul 7, 2020

Corvus Pharmaceuticals Initiates Clinical Trial of Novel Immunotherapy for Patients with COVID-19

Jul 7, 2020

NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors

Jul 7, 2020

Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China

Jul 6, 2020

Ascendis Pharma A/S Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan

Jul 6, 2020

BELLUS Health Announces Topline Results from its Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough

Jul 6, 2020

ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids

Jul 6, 2020

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

Jul 2, 2020

HARPOON THERAPEUTICS ANNOUNCES CHANGES TO BOARD OF DIRECTORS

Jul 1, 2020

scPharmaceuticals Announces FUROSCIX® NDA Resubmission

Jul 1, 2020

ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA

Jun 30, 2020

WEP Clinical Partners With Nabriva Therapeutics For The Named Patient Supply Of Xenleta® (Lefamulin)

Jun 30, 2020

Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and Development

Jun 30, 2020

TELA Bio Announces Closing of Public Offering of Common Stock

Jun 29, 2020

IMARA ADDED TO MEMBERSHIP OF U.S. SMALL-CAP RUSSELL 2000® INDEX

Jun 29, 2020

Verrica Pharmaceuticals Provides Regulatory Update on VP-102

Jun 26, 2020

Passage Bio Added to Russell 2000 Index

Jun 26, 2020

Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency

Jun 25, 2020

Fusion Pharmaceuticals Announces Pricing Of Initial Public Offering

Jun 25, 2020

Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002, a TREM2 Activating Antibody for the Treatment of Alzheimer’s Disease, in The Journal of Experimental Medicine

Jun 25, 2020

IMARA ANNOUNCES RECIPIENTS OF REAL IMPACT GRANTS PROGRAM TO SUPPORT PEOPLE AFFECTED BY RARE GENETIC BLOOD DISORDERS

Jun 24, 2020

Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies

Jun 24, 2020

IMARA RECEIVES ORPHAN DRUG DESIGNATION FOR IMR-687 FOR TREATMENT OF BETA-THALASSEMIA

Jun 23, 2020

Repare Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Jun 23, 2020

TELA Bio Announces Proposed Public Offering of Common Stock

Jun 23, 2020

Compass Therapeutics Completes Reverse Merger and Closes $60 Million Private Placement

Jun 23, 2020

Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics

Jun 23, 2020

Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics

Jun 22, 2020

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and GlaxoSmithKline’s Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple Myeloma

Jun 22, 2020

Arcutis Enrolls Last Patient in Phase 2 Proof of Concept Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis

Jun 22, 2020

Ikena Oncology Presents New Preclinical Data Highlighting the Anti-Cancer Effects of TEAD Inhibition on the Hippo Signaling Pathway

Jun 22, 2020

BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial

Jun 22, 2020

Turning Point Therapeutics’ Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer Models

Jun 22, 2020

ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II

Jun 22, 2020

TELA Bio, Inc. to Join the Russell 2000® Index

Jun 22, 2020

Ascendis Pharma A/S Announces Presentation of Preclinical Data for TransCon IL-2 ?/? at AACR Virtual Annual Meeting 2020

Jun 22, 2020

ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at the 2020 American Association for Cancer Research Virtual Annual Meeting II

Jun 19, 2020

Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for CONTEPO™ (fosfomycin) for injection

Jun 18, 2020

Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101

Jun 18, 2020

Valneva and Bavarian Nordic Announce Marketing and Distribution Partnership

Jun 18, 2020

Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases

Jun 17, 2020

Edgewise Therapeutics Appoints Kirsten L. Gruis, M.D., M.S. as Chief Medical Officer

Jun 16, 2020

Precision Oncology News: Kinnate Exiting Stealth Mode With Plans to Move Lead RAF Inhibitor Into Clinical Trials Next Year

Jun 16, 2020

Inspire Medical Systems, Inc. Announces Cigna Coverage for Inspire Therapy for the Treatment of Obstructive Sleep Apnea

Jun 15, 2020

Anthony Bihl Joins Sonendo® Board of Directors

Jun 15, 2020

Batavia Biosciences and Valneva Collaborate to Accelerate Development of Low-cost Inactivated Polio Vaccine

Jun 15, 2020

Augmedix Announces New Board Member, Jennifer M. Carter

Jun 12, 2020

Keros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050, along with Preclinical Data from its ALK2 Inhibitor Program, at the European Hematology Association 2020 Annual Meeting

Jun 12, 2020

X4 Pharmaceuticals Presents Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome at EHA 2020

Jun 12, 2020

IMARA PRESENTS POSITIVE INTERIM RESULTS FROM PHASE 2A STUDY OF IMR-687 IN SICKLE CELL DISEASE AT THE VIRTUAL EUROPEAN HEMATOLOGY ASSOCIATION ANNUAL CONGRESS

Jun 12, 2020

Verrica Pharmaceuticals Announces Positive Results from Two New Pooled Analyses of the Phase 3 CAMP Trials of VP-102 in Molluscum Contagiosum

Jun 12, 2020

Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib

Jun 11, 2020

Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout

Jun 11, 2020

CRINETICS PHARMACEUTICALS CONFIRMS COMPLETION FOR HALF OF THE ENROLLED PATIENTS IN THE ONGOING PHASE 2 ACROBAT EDGE CLINICAL TRIAL FOR PALTUSOTINE

Jun 11, 2020

X4 Pharmaceuticals Promotes Renato Skerlj, Ph.D., to Chief Scientific Officer

Jun 10, 2020

Verrica Pharmaceuticals Appoints Diem Nguyen, Ph.D., M.B.A., to its Board of Directors

Jun 9, 2020

ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors

Jun 9, 2020

Pandion Therapeutics Announces Issuance of U.S. Patent for Bifunctional Molecules Derived from TALON™ Platform

Jun 8, 2020

Glaukos Corporation Announces Pricing of Private Offering of $250 Million of 2.75% Convertible Senior Notes

Jun 8, 2020

Alpine Immune Sciences Provides Clinical Update of its Phase 1 Trial of ALPN-101 in Healthy Volunteers at the European League Against Rheumatism (EULAR) E-Congress 2020

Jun 8, 2020

Inspire Medical Systems, Inc. Announces Appointment of Medical Technology Industry Veteran Phil Ebeling as Chief Operating Officer

Jun 8, 2020

Ascendis Pharma A/S Announces Participation in ENDO Online 2020

Jun 5, 2020

Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jun 5, 2020

Menlo Therapeutics Announces Pricing of Offering of Common Stock

Jun 4, 2020

Alpine Immune Sciences Presents Preclinical Data on Novel Dual BAFF/APRIL Inhibitory Domains for B cell Mediated Autoimmune Diseases at the European Congress of Rheumatology E-Congress 2020

Jun 4, 2020

Silverback Therapeutics Appoints Vickie L. Capps to Board of Directors and Audit Committee Chair

Jun 4, 2020

89bio Appoints Veteran Finance Executive Lota Zoth to Board of Directors

Jun 4, 2020

Prevail Therapeutics Appoints Kira Schwartz, J.D., as General Counsel

Jun 2, 2020

Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris

Jun 2, 2020

WAKIX® (pitolisant) Data from Harmony Bioscienes Included on American Academy of Neurology Science Highlights Virtual Platform

Jun 2, 2020

Valneva Announces Publication in The Lancet of Complete Phase 1 Data for its Single-Shot Chikungunya Vaccine Candidate

Jun 1, 2020

HLS Therapeutics to Become Distributor of the Saladax MyCare� Psychiatry Line including the Insite Point-of-Care Device and Antipsychotic Reagents

Jun 1, 2020

Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator to Stimulate an Immune Response in Difficult to Treat Tumors

Jun 1, 2020

CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial

Jun 1, 2020

AbCellera’s Rapid Pandemic Response Platform Contributes to the World’s First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment

Jun 1, 2020

Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments

Jun 1, 2020

Ayisha Jeter Joins Arcutis as Vice President of Market Access

May 29, 2020

Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046

May 29, 2020

ObsEva SA to present at the Jefferies Virtual Healthcare Conference June 3rd, 2020

May 29, 2020

HARPOON THERAPEUTICS PRESENTS INTERIM PHASE 1 DATA FROM AN ONGOING DOSE ESCALATION TRIAL FOR THE PSMA-TARGETING TRITAC® HPN424 AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAM

May 29, 2020

Corvus Pharmaceuticals Presents Updated Clinical Data Supporting and Refining the Adenosine Gene Signature’s Ability to Identify Patients Likely to Respond to Treatment with Ciforadenant

May 29, 2020

Menlo Therapeutics Receives FDA Approval of ZILXI™ (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosacea

May 29, 2020

NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting

May 28, 2020

resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19 in Nursing Home Residents

May 27, 2020

resTORbio Provides Corporate Update and Reports First Quarter 2020 Financial Results

May 27, 2020

Kinnate Biopharma Appoints Nima Farzan as Chief Executive Officer

May 27, 2020

CRINETICS PHARMACEUTICALS APPOINTS ADRIANA CABRÉ, MBA, AS VICE PRESIDENT OF HUMAN RESOURCES

May 27, 2020

Jay Ramsinghani Joins Arcutis as Vice President of Commercial Strategy and Operations

May 27, 2020

Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity

May 27, 2020

Turning Point Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

May 27, 2020

Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 Patients

May 27, 2020

AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug Discovery Platform

May 26, 2020

KALA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR EYSUVIS™ FOR DRY EYE DISEASE

May 26, 2020

TransMedics Announces Pricing of Public Offering of Common Stock

May 26, 2020

Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer

May 26, 2020

Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers Squibb

May 26, 2020

SpringWorks Therapeutics Appoints Julie Hambleton, M.D. to its Board of Directors

May 26, 2020

Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology

May 26, 2020

TransMedics Announces Positive Top-line Results from U.S. Pivotal OCS� Liver PROTECT Trial

May 22, 2020

AbCellera Announces Multi-Year Antibody Discovery Collaboration with Lilly

May 22, 2020

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results

May 22, 2020

Tricida Announces Closing of Offering of $200 Million of 3.50% Convertible Senior Notes Due 2027, Including Full Exercise of Option to Purchase Additional Notes

May 21, 2020

Passage Bio Receives Rare Pediatric Disease Designation for PBGM01 for Patients with GM1 Gangliosidosis

May 21, 2020

Xenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

May 21, 2020

Synlogic Announces Termination of AbbVie Collaboration Agreement

May 20, 2020

ORIC Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results

May 20, 2020

scPharmaceuticals Announces Pricing of Public Offering of Common Stock

May 20, 2020

New Alliance Maps the Way in Electrophysiology

May 19, 2020

Ascendis Pharma A/S Reports First Quarter 2020 Financial Results

May 19, 2020

Pandion Therapeutics Appoints John S. Sundy, M.D., Ph.D., as Chief Medical Officer

May 19, 2020

Galecto Appoints New Chair and Strengthens Board of Directors

May 18, 2020

Graybug Vision Appoints Parisa Zamiri, Physician-Scientist with Deep Expertise in Ophthalmology, as Chief Medical Officer

May 18, 2020

National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the United States From Blood and Respiratory Tract Cultures Approaches 40 Percent

May 15, 2020

ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting

May 14, 2020

X4 Pharmaceuticals Announces Data from Phase 2 Open-Label Extension Trial of Mavorixafor in WHIM Syndrome as Published in EHA Abstract

May 14, 2020

BELLUS Health Reports First Quarter 2020 Financial Results and Business Highlights, and Provides Updates on BLU-5937

May 14, 2020

Prevail Therapeutics Reports First Quarter 2020 Financial Results and Business Highlights

May 14, 2020

Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program

May 14, 2020

Alpine Immune Sciences Reports First Quarter 2020 Financial Results and Provides Company Update

May 13, 2020

Alector Reports 2020 First Quarter Financial Results and Business Highlights

May 13, 2020

89bio Reports First Quarter 2020 Financial Results and Provides Corporate Update

May 12, 2020

Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Update on Operations and COVID-19 Response

May 12, 2020

TELA Bio Announces First Quarter 2020 Financial Results

May 12, 2020

Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924)

May 12, 2020

scPharmaceuticals Inc. Reports First Quarter 2020 Financial Results and Provides Business Update

May 12, 2020

Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy

May 12, 2020

SpringWorks Therapeutics Reports First Quarter 2020 Financial Results and Recent Business Highlights

May 12, 2020

Arcutis Announces First Quarter 2020 Financial Results and Provides Business Update

May 11, 2020

Augmedix Introduces New Services that Increase Clinician Productivity and Enhance the Clinician-Patient Relationship

May 11, 2020

Ascendis Pharma A/S Will Appoint Jesper Høiland as Global Chief Commercial Officer

May 11, 2020

Passage Bio Reports First Quarter 2020 Financial Results and Recent Business Highlights

May 11, 2020

Nabriva Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Updates

May 8, 2020

CRINETICS PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 8, 2020

Synlogic Reports First Quarter 2020 Financial Results and Provides Business Update

May 7, 2020

Tricida Announces First Quarter 2020 Financial Results

May 7, 2020

KALA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 7, 2020

Intellia Therapeutics Announces First Quarter 2020 Financial Results

May 7, 2020

Glaukos Corporation Announces First Quarter 2020 Financial Results

May 7, 2020

Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate Highlights

May 7, 2020

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2020

May 7, 2020

Aerpio Reports First Quarter 2020 Financial Results and Provides Business Update

May 7, 2020

Gemini Therapeutics Appoints Marc E. Uknis, MD, FACS as Chief Medical Officer

May 7, 2020

Verrica Pharmaceuticals Reports First Quarter 2020 Financial Results

May 7, 2020

Passage Bio Announces Expansion of Gene Therapy Collaboration with University of Pennsylvania

May 7, 2020

CTI BioPharma Reports First Quarter 2020 Financial Results

May 7, 2020

IMARA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

May 7, 2020

Sierra Oncology Reports First Quarter 2020 Results

May 7, 2020

X4 Pharmaceuticals Provides Corporate Update, Including Expected Impact of COVID-19, and Reports First Quarter 2020 Financial Results

May 7, 2020

NextCure Reports First Quarter 2020 Financial Results

May 7, 2020

Selecta Biosciences Reports First Quarter 2020 Financial Results

May 6, 2020

Galecto Advances Phase 2b Study of GB0139 in Idiopathic Pulmonary Fibrosis; Recruitment Remains on Track Despite COVID-19 Crisis

May 6, 2020

HARPOON THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 6, 2020

IMARA LAUNCHES ‘REAL IMPACT’ COMMUNITY SUPPORT PROGRAM TO ADDRESS UNMET NEEDS AFFECTING PEOPLE WITH RARE GENETIC BLOOD DISORDERS

May 5, 2020

XENLETA® (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response in Hospitalized Patients with Community-Acquired Bacterial Pneumonia (CABP)

May 5, 2020

ObsEva Announces First Quarter 2020 Financial Results and Business Update

May 5, 2020

Inspire Medical Systems, Inc. Announces First Quarter 2020 Financial Results

May 4, 2020

IMARA ANNOUNCES APPOINTMENT OF STEPHEN M. MIGAUSKY AS GENERAL COUNSEL

May 4, 2020

Galecto presents GB0139 preclinical and clinical data on anti-fibrotic activity as online Experimental Biology 2020 poster

May 3, 2020

AbCellera Receives $175.6 million from the Government of Canada to Discover Solutions for COVID-19 and Build a Manufacturing Facility for Antibody Drugs

Apr 30, 2020

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results

Apr 30, 2020

Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020

Apr 30, 2020

Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer

Apr 30, 2020

Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15

Apr 30, 2020

Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Apr 29, 2020

resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology

Apr 29, 2020

resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology

Apr 29, 2020

Aspen Neuroscience Announces Addition to Board of Directors

Apr 28, 2020

Gemini Therapeutics Appoints David Lubner as Independent Director

Apr 28, 2020

Selecta Biosciences Appoints Dr. Goran Ando to its Board of Directors

Apr 28, 2020

ORIC Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Apr 27, 2020

Halley E. Gilbert Appointed to Arcutis Board of Directors

Apr 27, 2020

HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN217, A BCMA TARGETING TRITAC, FOR MULTIPLE MYELOMA

Apr 27, 2020

CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19

Apr 27, 2020

Galecto Appoints Jonathan Freve as Chief Financial Officer

Apr 23, 2020

TELA Bio Announces Changes to its Board of Directors

Apr 23, 2020

Imara Strengthens Board of Directors With Appointment of Edward R. Conner, M.D.

Apr 23, 2020

Menlo Therapeutics and Cutia Therapeutics Enter into Exclusive License Agreement for AMZEEQ™ and Approved Topical Minocycline Products in Greater China

Apr 22, 2020

Valneva and Dynavax Announce Collaboration to Advance Vaccine Development for COVID-19

Apr 22, 2020

Silverback Therapeutics Announces Appointment of Veteran Executive Laura Shawver, Ph.D. as President and CEO

Apr 21, 2020

Inspire Medical Systems Announces FDA Approval of Expanded Age Range for Inspire Therapy

Apr 21, 2020

Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema

Apr 21, 2020

Nature Communications Highlights Research by Scientists at Graybug Vision and Johns Hopkins University on Sustained Treatment of Retinal Diseases

Apr 19, 2020

Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon™ PTH as a Replacement Therapy for Hypoparathyroidism

Apr 17, 2020

Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Apr 16, 2020

Clinical Cancer Research Highlights Potent Antitumor Activity of Repotrectinib in Treatment-Naïve and Solvent-Front Mutation Ros1-Positive Non-Small Cell Lung Cancer

Apr 16, 2020

Inspire Medical Systems, Inc. Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Apr 16, 2020

TigerConnect Launches TigerTouch Video and Voice Telehealth Features to Help Hospitals Combat COVID-19

Apr 15, 2020

Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon™ hGH as Treatment for Growth Hormone Deficiency in the United States

Apr 15, 2020

Carl Gordon named to 2020 Forbes Midas List of top venture capitalists

Apr 14, 2020

ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares

Apr 13, 2020

Inspire Medical Systems, Inc. Provides First Quarter and Full Year 2020 Update

Apr 13, 2020

Arvinas Provides Update on Business Continuity Related to the Impact of the COVID-19 Pandemic

Apr 13, 2020

89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial and Reports New Preclinical Data Confirming BIO89-100’s Mechanism of Action Via Potent FGF Receptor Agonism

Apr 13, 2020

NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 Pandemic

Apr 9, 2020

Glaukos Provides Update on COVID-19 Impact and Preliminary Net Sales Range for the First Quarter of 2020

Apr 9, 2020

Centers for Medicare & Medicaid Services Issues Product-Specific J-Code for XENLETA

Apr 8, 2020

Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

Apr 7, 2020

Keros Therapeutics Announces Pricing of Initial Public Offering of Common Stock

Apr 7, 2020

X4 Pharmaceuticals Showcases Strategic Focus on WHIM Syndrome During 2020 Analyst Day Webinar

Apr 6, 2020

Aspen Neuroscience Announces Reconstitution of the Board of Directors with the Addition of Seasoned Industry Executives

Apr 6, 2020

CRINETICS PHARMACEUTICALS REPORTS POSITIVE INTERIM RESULTS FOR THE ACROBAT EDGE PHASE 2 TRIAL OF PALTUSOTINE (CRN00808) IN ACROMEGALY PATIENTS AND PROVIDES CORPORATE UPDATE

Apr 6, 2020

BELLUS Health Announces Completion of Dosing in Phase 2 RELIEF Trial with BLU-5937 for the Treatment of Refractory Chronic Cough

Apr 6, 2020

ObsEva SA Announces New Interim Chief Financial Officer

Apr 3, 2020

resTORbio Announces Delay of its Ongoing Phase 1b/2a trial of RTB101 in Patients with Parkinson’s Disease Due to COVID-19 Level 4 Alert in New Zealand

Apr 2, 2020

ORIC PHARMACEUTICALS APPOINTS CHRISTIAN V. KUHLEN, M.D., AS GENERAL COUNSEL

Apr 1, 2020

Pandion Therapeutics Announces Close of $80 Million Series B Financing

Apr 1, 2020

HARPOON THERAPEUTICS APPOINTS TWO NEW MEMBERS TO ITS BOARD OF DIRECTORS

Apr 1, 2020

Aspen Neuroscience Announces $70 Million Series A Financing Led by OrbiMed to Advance Development of the First Autologous Neuron Replacement Therapy to Treat Parkinson Disease

Apr 1, 2020

Ascendis Pharma A/S Reports Full-Year 2019 Financial Results

Mar 31, 2020

FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics

Mar 31, 2020

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL AND SPECIAL

Mar 31, 2020

Xenon Pharmaceuticals Provides Corporate Update in the Context of COVID-19

Mar 31, 2020

Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD

Mar 31, 2020

Health Catalyst Launches Four Additional COVID-19 Solutions and a Modular Bundle

Mar 30, 2020

Compass Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy and Safety of CTX-471, a Unique Fully Human Agonist of CD137

Mar 30, 2020

Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational Activities

Mar 30, 2020

NextCure Announces Appointment of Veteran Oncology Executive Garry Nicholson to its Board of Directors

Mar 30, 2020

Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

Mar 30, 2020

Harmony Biosciences Highlights Publication of Narcolepsy Treatment Scientific Review in Sleep Medicine

Mar 27, 2020

TELA Bio Announces Fourth Quarter and Full Year 2019 Financial Results

Mar 26, 2020

Prevail Therapeutics Reports Full Year 2019 Financial Results and Business Highlights

Mar 25, 2020

89bio Appoints Healthcare Industry Veteran Steven Altschuler, M.D., as Chairman of the Board of Directors

Mar 25, 2020

Alector Enters into a Licensing Agreement with Innovent Biologics to Develop and Commercialize AL008 in Oncology Indications in China

Mar 25, 2020

BELLUS Health Announces Closing of Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations

Mar 24, 2020

Glaukos Provides COVID-19 Pandemic Update

Mar 24, 2020

scPharmaceuticals Inc. Reports Fourth Quarter and Year Ended 2019 Financial Results and Provides Business Update

Mar 24, 2020

Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR006 to Slow the Progression of Frontotemporal Dementia with a GRN Mutation

Mar 24, 2020

Health Catalyst Expands COVID-19 Response Support and Provides Infrastructure to Enable Readiness for Future Demands

Mar 24, 2020

Alector Reports 2019 Fourth Quarter and Full Year Financial Results and Business Highlights

Mar 23, 2020

Kimberly Lathroum Joins Arcutis as Vice President of Marketing

Mar 23, 2020

ObsEva Provides Update Related to COVID-19 Pandemic

Mar 23, 2020

Alector Announces the Appointment of Paula Hammond, Ph.D., to the Board of Directors

Mar 23, 2020

Fusion Pharmaceuticals Appoints James J. O’Leary, M.D. As Chief Medical Officer

Mar 20, 2020

Verona Pharma plc: Issue of Equity and Total Voting Rights

Mar 19, 2020

BELLUS Health Announces Completion of Enrollment in Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough

Mar 18, 2020

89bio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Mar 18, 2020

SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039

Mar 18, 2020

Alpine Immune Sciences’ ALPN-101 Receives FDA Orphan Drug Designations for the Prevention and Treatment of Acute Graft Versus Host Disease

Mar 17, 2020

Health Catalyst Plans to Support Health System Clients� COVID-19 Response with Three Initial Solutions Focused on Patient Tracking, Public Health Surveillance and Staff Augmentation Support

Mar 16, 2020

TURNING POINT THERAPEUTICS REPORTS FOURTH-QUARTER, FULL- YEAR 2019 FINANCIAL AND OPERATIONAL RESULTS

Mar 16, 2020

Aerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

Mar 16, 2020

Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis

Mar 16, 2020

Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Mar 13, 2020

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results

Mar 12, 2020

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

Mar 12, 2020

resTORbio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Mar 12, 2020

Selecta Biosciences Reports Fourth Quarter 2019 and Year-End Financial Results

Mar 12, 2020

Synlogic Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

Mar 12, 2020

HARPOON THERAPEUTICS REPORTS FOURTH QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 12, 2020

X4 Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

Mar 12, 2020

Nabriva Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results and Recent Corporate Highlights

Mar 12, 2020

AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19

Mar 12, 2020

CTI BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results

Mar 12, 2020

Sonendo® Appoints Amit Agarwal as Vice President of Marketing

Mar 11, 2020

Verrica Pharmaceuticals Secures $55 Million in Loan Facilities Led by Silicon Valley Bank

Mar 11, 2020

Silverback Therapeutics Raises $78.5 Million in Oversubscribed Series B Financing

Mar 10, 2020

KALA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF 16,000,000 SHARES OF COMMON STOCK

Mar 9, 2020

Tricida Hires Robert McKague as Executive Vice President, General Counsel & Chief Compliance Officer

Mar 9, 2020

Xenon Pharmaceuticals Reports 2019 Financial Results and Provides Corporate Update

Mar 9, 2020

CRINETICS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 9, 2020

NeuroPace RNS System Receives FDA Approval for MRI Labeling, Allowing Thousands More Patients to Benefit from Personalized, Data-Driven Epilepsy Treatment

Mar 9, 2020

KALA PHARMACEUTICALS ANNOUNCES STATISTICALLY SIGNIFICANT RESULTS FOR PRIMARY AND KEY SECONDARY ENDPOINTS IN STRIDE 3 CLINICAL TRIAL EVALUATING EYSUVIS™ FOR SIGNS AND SYMPTOMS OF DRY EYE DISEASE

Mar 6, 2020

CTI BioPharma Announces Closing of Rights Offering

Mar 6, 2020

Keros Therapeutics Closes $56 Million Series C Financing to Advance its Programs in Hematologic and Musculoskeletal Disorders

Mar 5, 2020

Heather Rowe Armstrong Joins Arcutis as Vice President of Investor Relations and Corporate Communications

Mar 5, 2020

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results

Mar 5, 2020

ObsEva Announces Year End 2019 Financial Results and Business Update

Mar 5, 2020

Passage Bio Appoints Athena Countouriotis to Board of Directors

Mar 4, 2020

Fusion Pharmaceuticals Announces Appointment Of Steven Gannon To Board Of Directors

Mar 3, 2020

Prevail Therapeutics Provides Clinical Advancement Update on PR001 for the Treatment of Parkinson’s Disease with GBA1 mutations

Mar 3, 2020

Sierra Oncology Reports 2019 Year End Results

Mar 2, 2020

ORIC PHARMACEUTICALS APPOINTS MARDI C. DIER TO ITS BOARD OF DIRECTORS

Mar 2, 2020

Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN Mutation

Feb 28, 2020

Graybug Vision presents preclinical results for GB-401, a potential sustained-delivery treatment of up to six months for primary open angle glaucoma, at the American Glaucoma Society Annual Meeting

Feb 27, 2020

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL AND SPECIAL

Feb 27, 2020

Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update

Feb 27, 2020

Glaukos Corporation Announces Fourth Quarter and Full Year 2019 Financial Results

Feb 27, 2020

BELLUS Health Reports Full Year 2019 Financial Results and Business Highlights on BLU-5937

Feb 27, 2020

Tricida Announces Fourth Quarter and Full-Year 2019 Financial Results

Feb 27, 2020

Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update

Feb 27, 2020

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results

Feb 27, 2020

Passage Bio Announces Pricing of Initial Public Offering

Feb 27, 2020

MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors

Feb 26, 2020

Numerous Presentations to Showcase Long-Term Efficacy & Safety of Glaukos Technologies at 2020 American Glaucoma Society Meeting

Feb 26, 2020

Gemini Therapeutics and Singapore Eye Research Institute Enter Into Research Collaboration to Explore New Targets for Age-related Macular Degeneration

Feb 25, 2020

Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2019 Financial Results and Provides 2020 Guidance

Feb 24, 2020

Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones

Feb 20, 2020

Turning Point Therapeutics Names Siegfried Reich as Executive Vice President and Chief Scientific Officer

Feb 19, 2020

resTORbio Announces Interim Results for Phase 1b/2a Trial of RTB101 in Patients with Parkinson’s Disease and Provides Corporate Update

Feb 18, 2020

Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer

Feb 14, 2020

CTI BioPharma Announces Commencement of Rights Offering

Feb 14, 2020

Xenon Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares

Feb 14, 2020

Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research

Feb 13, 2020

Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis

Feb 13, 2020

Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b/2 Clinical Trial of Ciforadenant at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers Symposium

Feb 12, 2020

X4 Pharmaceuticals Granted New Composition of Matter Patent for Late-Stage Clinical Candidate Mavorixafor

Feb 12, 2020

Kala Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial Results

Feb 12, 2020

Prevail Therapeutics’ PR001 Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA

Feb 10, 2020

Essa Pharma Announces Multiple Abstracts Accepted For Presentation At Upcoming Medical And Scientific Symposia

Feb 10, 2020

Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference

Feb 7, 2020

Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort Showing Potential of Topical Ocular Formulation of AKB-9778 Product Candidate When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension

Feb 7, 2020

Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares

Feb 6, 2020

Fusion Pharmaceuticals Announces Appointment Of Pablo J. Cagnoni, M.D., To Board Of Directors

Feb 6, 2020

Imara Appoints Joelle Lufkin, M.P.H., as Senior Vice President of Development

Feb 6, 2020

Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to Gilead

Feb 6, 2020

VectivBio Adds Commercial Expertise with the Appointment of Kevin Harris as Chief Commercial Officer

Feb 6, 2020

Sonendo® Appoints Andrew Kirkpatrick as Chief Operating Officer

Feb 5, 2020

Alector Announces FDA Fast Track Designation Granted to AL101 for the Treatment of Patients with Frontotemporal Dementia

Feb 4, 2020

Arcutis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Feb 4, 2020

TELA Bio Announces Publication of Results from In-Vivo Study Demonstrating Favorable Response to Reinforced Biologics in Hernia Repair

Feb 3, 2020

Alector Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 3, 2020

Valneva Announces New $85 Million Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed

Feb 3, 2020

Verona Pharma Announces Senior Management Changes

Feb 3, 2020

Galecto Appoints Industry Leader Bertil Lindmark, MD, PhD, as Chief Medical Officer

Feb 3, 2020

CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib in Treating Myelofibrosis Patients With Severe Thrombocytopenia

Feb 3, 2020

OrbiMed Announces New General Partner

Feb 3, 2020

Inspire Medical Systems, Inc. Announces Medicare Policy Release Dates and New Draft Local Coverage Determination for Remaining Region

Feb 1, 2020

Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1/1b Clinical Trial of CPI-818 at the 12th Annual T-Cell Lymphoma Forum

Jan 30, 2020

Synlogic Appoints Dr. Michael Burgess to its Board of Directors

Jan 29, 2020

Verrica Pharmaceuticals Announces the Hiring of Two Vice Presidents to Further Grow its Commercial Capabilities

Jan 29, 2020

TELA Bio Announces Appointment of New Chief Commercial Officer

Jan 28, 2020

Alector Announces Initiation of Phase 1b Study of AL003 in Alzheimer’s Disease Patients

Jan 28, 2020

Passage Bio Appoints Bruce Goldsmith, Ph.D. as Chief Executive Officer

Jan 28, 2020

Ikena Oncology Announces Dosing of First Patient in Phase 1 Study Evaluating IK-175 in Patients with Advanced Solid Tumors

Jan 27, 2020

Alector Announces Proposed Public Offering of Common Stock

Jan 27, 2020

Harmony Biosciences Secures $200 Million Debt Facility

Jan 27, 2020

ReViral’s Phase 2a RSV Study publication selected as Editor’s Pick in February 2020 issue of ASM’s Antimicrobial Agents and Chemotherapy

Jan 27, 2020

ORIC Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial of ORIC-101 in Combination with XTANDI® for the Treatment of Prostate Cancer in Collaboration with Astellas

Jan 24, 2020

Alpine Immune Sciences Presents New Preclinical Data at 2020 Crohn's & Colitis Congress ALPN-101 demonstrates efficacy in treatment of chronic inflammatory bowel disease in both in vivo and in vitro models

Jan 23, 2020

Turning Point Therapeutics Names Garry Nicholson to Its Board of Directors

Jan 22, 2020

Xenon Pharmaceuticals Announces Pricing of $60.0 Million Public Offering of Common Shares

Jan 22, 2020

Sierra Oncology Announces Reverse Stock Split

Jan 22, 2020

TigerConnect Names New Chief Technology Officer as it Accelerates Product Innovation

Jan 22, 2020

Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares

Jan 21, 2020

Arcutis Announces ARQ-154 Program for Scalp Psoriasis and Enrollment of First Patient in Phase 2b Clinical Trial

Jan 18, 2020

Verrica Pharmaceuticals Announces Presentation of Positive Data from New Pooled Analysis of Phase 3 CAMP Trials of VP-102

Jan 15, 2020

Patricia Turney Joins Arcutis as Senior Vice President, Manufacturing

Jan 15, 2020

Kala Pharmaceuticals Announces Completion of Enrollment of STRIDE 3 Trial for EYSUVIS™ (KPI-121 0.25%) for Dry Eye Disease

Jan 14, 2020

Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies

Jan 14, 2020

Adimab Extends Platform Partnership with Novo Nordisk

Jan 13, 2020

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update

Jan 13, 2020

Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma

Jan 13, 2020

Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications

Jan 13, 2020

Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

Jan 13, 2020

Fusion Pharmaceuticals Announces Investment from Canada Pension Plan Investment Board (CPPIB)

Jan 13, 2020

Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

Jan 13, 2020

ObsEva and Yuyuan BioScience Technology Announce Sublicense Agreement to Develop and Commercialize Nolasiban in the People’s Republic of China

Jan 13, 2020

Turning Point Therapeutics Announces Program Updates and Milestones for 2020

Jan 13, 2020

KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814

Jan 13, 2020

Arcutis Announces Exercise of Option for Exclusive License to Highly Selective JAK1 Inhibitor for All Topical Dermatological Uses in U.S., Canada, Europe and Japan

Jan 13, 2020

Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership

Jan 13, 2020

Adimab Provides 2019 Update on Clinical Pipeline

Jan 12, 2020

Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference

Jan 10, 2020

Passage Bio Appoints Sandip Kapadia to Board of Directors

Jan 10, 2020

TELA Bio Announces Preliminary Revenue for Fourth Quarter and Full Year 2019

Jan 10, 2020

Adimab Provides Year-End Update on 2019 Partnership Activities

Jan 10, 2020

TERNS PHARMACEUTICALS PRESENTS RESULTS FROM AN ONGOING PHASE 1 CLINICAL TRIAL OF TERN-201, A SSAO INHIBITOR IN DEVELOPMENT FOR NASH

Jan 9, 2020

Turning Point Therapeutics Announces Management Transition

Jan 9, 2020

Prevail Therapeutics Provides PR001 Program Update

Jan 9, 2020

Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular Degeneration

Jan 9, 2020

Aspen Neuroscience Announces Board of Directors and Scientific Advisory Board

Jan 9, 2020

Synlogic Outlines Upcoming Milestones for Clinical Programs and Unveils New Preclinical Pipeline Programs

Jan 9, 2020

Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones

Jan 8, 2020

Nabriva Therapeutics Receives FDA Acknowledgement of New Drug Application Resubmission for Intravenous CONTEPO™ (fosfomycin) for Injection

Jan 8, 2020

Topical Ocular Formulation of Aerpio Pharmaceutical's AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b Trial

Jan 8, 2020

Arcutis Announces Enrollment of First Patients in Two Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 as a Potential Once Daily Topical Treatment for Plaque Psoriasis

Jan 7, 2020

Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations

Jan 7, 2020

VectivBio Launches with $35M Financing to Bring Best-in-Disease Medicines to Patients with Serious Rare Diseases

Jan 7, 2020

Galecto and PharmAkea merge to create strong clinical-stage company developing first-in-class therapeutics in fibrosis and cancer

Jan 6, 2020

Turning Point Therapeutics Names Homa Yeganegi Senior Vice President, Project Team Leader and Head of Medical Affairs

Jan 6, 2020

Arcutis Biotherapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering

Jan 6, 2020

Alector Initiates First-in-Human Dosing in Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

Jan 6, 2020

Sonendo® Announces Growth Investment from EW Healthcare Partners

Dec 31, 2019

HLS Therapeutics Announces Health Canada Approval for Vascepa® to Reduce the Risk of Cardiovascular Events

Dec 30, 2019

Principia Updates PRN1008 Pemphigus Clinical Program

Dec 30, 2019

X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor in Combination with Ibrutinib for the Treatment of Waldenström’s Macroglobulinemia (WM)

Dec 20, 2019

Nabriva Therapeutics Announces $20 Million Registered Direct Offering

Dec 20, 2019

Nabriva Therapeutics Resubmits New Drug Application for Intravenous CONTEPO™ (fosfomycin) for Injection

Dec 20, 2019

Alector Added to the NASDAQ Biotechnology Index

Dec 13, 2019

Alector Appoints Dr. Richard Scheller, Lasker Prize Awarded Scientist, and Dr. Thomas Südhof, Nobel Laureate as Co-Chairs of its Strategic Portfolio Advice and Review Committee

Dec 13, 2019

Alector Showcases Progress in Immuno-Neurology Clinical Programs and Research Portfolio at R&D Day

Dec 12, 2019

AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease

Dec 12, 2019

Selecta Biosciences Announces $70 Million Private Placement

Dec 12, 2019

Selecta Biosciences Announces Completion of Enrollment in Head-to-Head COMPARE Trial of SEL-212

Dec 11, 2019

Alector Announces Appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as President and Chief Operating Officer

Dec 11, 2019

PMV Pharma Appoints Leila Alland, M.D., as Chief Medical Officer

Dec 9, 2019

CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Benefit in Myelofibrosis Patients with Severe Thrombocytopenia at the 61st American Society of Hematology Meeting

Dec 9, 2019

Alpine Immune Sciences Presents ALPN-101 Phase 1 Healthy Volunteer Study Data and Details of Upcoming Phase I/II BALANCE GVHD Study at the 61st American Society of Hematology Annual Meeting

Dec 9, 2019

ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix

Dec 8, 2019

Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion

Dec 7, 2019

Principia Presents Consistent Positive Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial

Dec 7, 2019

Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual Meeting

Dec 6, 2019

Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

Dec 5, 2019

Alector Announces FDA Fast Track Designation Granted to AL001 for the Treatment of Patients with Frontotemporal Dementia

Dec 4, 2019

TransMedics’ Organ Care System (OCS™) Technology Used in First U.S. Adult Human Heart Transplants From DCD Donors

Dec 3, 2019

Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP?A2M4 for the Treatment of Synovial Sarcoma

Dec 3, 2019

Tricida Announces Hiring of Elizabeth Faust, Ph.D., as Senior Vice President of Medical Affairs

Nov 27, 2019

ReViral Appoints Lawrence Blatt and Richard N. Kender to its Board of Directors

Nov 26, 2019

X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants

Nov 25, 2019

X4 Pharmaceuticals Announces Proposed Public Offering

Nov 21, 2019

Selecta Biosciences Appoints Carrie S. Cox as Chairman of its Board of Directors

Nov 21, 2019

Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors

Nov 21, 2019

Glaukos Completes Acquisition of Avedro, Inc.

Nov 21, 2019

Harpoon Therapeutics And Abbvie Announce Licensing And Option Collaboration To Advance Hpn217, Harpoon’s Bcma-Targeting Tritac®, And Expand Existing Discovery Collaboration

Nov 19, 2019

NextCure Announces Closing of Public Offering

Nov 19, 2019

Verrica Pharmaceuticals Announces Passing of Board of Directors Member Glenn Oclassen

Nov 18, 2019

Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results

Nov 18, 2019

Phase 2a Study Published in Antimicrobial Agents and Chemotherapy Shows Potential of Sisunatovir (RV521) to Combat Respiratory Syncytial Virus Infection

Nov 18, 2019

Prevail Therapeutics Announces Appointment of Morgan Sheng, Ph.D., to Board of Directors

Nov 18, 2019

Nabriva Therapeutics Commends the CDC on the 2019 Antibiotic Resistance Threats Report, Highlighting the Need for New Antibiotics Aligned with Antibiotic Stewardship

Nov 16, 2019

Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma

Nov 15, 2019

resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint

Nov 14, 2019

Tricida Announces Third Quarter 2019 Financial Results

Nov 14, 2019

Tricida Announces FDA Acceptance of New Drug Application for Veverimer

Nov 14, 2019

Verona Pharma plc: PDMR Dealing – Purchase by Chairman

Nov 14, 2019

Arcutis Appoints Keith Klein as General Counsel

Nov 14, 2019

Ascendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States

Nov 14, 2019

BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2019

Nov 14, 2019

NextCure Announces Pricing of Public Offering of Common Stock

Nov 13, 2019

PMV Pharma Secures $62 Million in Series C Financing To Develop Cancer Drugs Targeting p53

Nov 12, 2019

Synlogic Provides Program and Business Update and Reports Third Quarter 2019 Financial Results

Nov 12, 2019

NextCure Reports Third Quarter 2019 Financial Results

Nov 12, 2019

Prevail Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

Nov 12, 2019

Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients

Nov 12, 2019

Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Nov 12, 2019

SpringWorks Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

Nov 12, 2019

Alector Reports Recent Business Highlights and Third Quarter 2019 Financial Results

Nov 12, 2019

scPharmaceuticals Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

Nov 12, 2019

Alpine Immune Sciences Presents New ALPN-101 Preclinical Data at the 2019 American College of Rheumatology (ACR) Annual Meeting

Nov 12, 2019

X4 Pharmaceuticals Receives Breakthrough Therapy Designation from the FDA for Mavorixafor for the Treatment of WHIM Syndrome

Nov 12, 2019

Nabriva Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

Nov 11, 2019

Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

Nov 11, 2019

Selecta Biosciences Presents New Data at 2019 American College of Rheumatology Annual Meeting from Phase 2 Study of SEL-212 for the Treatment of Patients with Chronic Refractory Gout

Nov 11, 2019

Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor

Nov 11, 2019

89bio Announces Pricing of Upsized Initial Public Offering

Nov 11, 2019

SI-BONE, Inc. Reports Third Quarter 2019 Financial Results and Updates Full-Year 2019 Revenue Guidance

Nov 9, 2019

NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the Trial

Nov 8, 2019

Selecta Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Nov 8, 2019

Alpine Immune Sciences Presents New Preclinical Data at The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

Nov 8, 2019

Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 7, 2019

Aerpio Reports Third Quarter 2019 Financial Results and Provides Business Update

Nov 7, 2019

X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights

Nov 7, 2019

Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary Endpoint

Nov 7, 2019

ObsEva Announces Third Quarter 2019 Financial Results

Nov 7, 2019

TELA Bio Announces Pricing of Initial Public Offering of Common Stock

Nov 7, 2019

Kala Reports Third Quarter 2019 Financial Results

Nov 7, 2019

Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Nov 6, 2019

Verrica Pharmaceuticals Reports Third Quarter 2019 Financial Results

Nov 6, 2019

Alpine Immune Sciences Announces Oral Presentation of ALPN-101 at the 61st American Society of Hematology Annual Meeting and Exposition

Nov 6, 2019

Arvinas Announces Proposed Offering of Common Stock

Nov 6, 2019

Arvinas Announces Pricing of Public Offering of Common Stock

Nov 6, 2019

Harpoon Therapeutics Reports Third Quarter 2019 Financial Results And Provides Corporate Update

Nov 6, 2019

Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update

Nov 6, 2019

Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2019 Financial Results

Nov 6, 2019

Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights

Nov 6, 2019

Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon™ Technology in Oncology at SITC 2019

Nov 5, 2019

Xenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Nov 5, 2019

X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor for the Treatment of Severe Congenital Neutropenia

Nov 5, 2019

Inspire Medical Systems, Inc. Announces Third Quarter 2019 Financial Results and Increases 2019 Outlook

Nov 5, 2019

Silverback Therapeutics to Present Preclinical Data at SITC 34th Annual Meeting Demonstrating SBT6050’s Potential for Robust Single Agent Activity in Tumors Refractory to Checkpoint Inhibition

Nov 5, 2019

Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019

Nov 5, 2019

Synthorx Reports Third Quarter Financial Results

Nov 5, 2019

resTORbio Reports Third Quarter 2019 Financial Results and Corporate Update

Nov 5, 2019

Principia Biopharma reports third quarter financial results

Nov 4, 2019

Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Nov 4, 2019

Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial Officer

Nov 4, 2019

CTI BioPharma Reports Third Quarter 2019 Financial Results

Nov 4, 2019

SI-BONE Announces Medicare Physician Payment Increase of 27% for Minimally Invasive SI Joint Fusion

Nov 4, 2019

Turning Point Therapeutics Reports Third Quarter 2019 Financial and Operational Results

Nov 4, 2019

X4 Pharmaceuticals Appoints Derek Meisner, J.D., as General Counsel

Nov 1, 2019

ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF

Oct 31, 2019

Promentis Pharmaceuticals Announces Positive Results for Phase 2A Study of SXC-2023 Targeting Novel Glutamatergic Mechanism and Completion of Enrollment for Phase 2 Trichotillomania Study

Oct 31, 2019

Intellia Therapeutics Announces Third Quarter 2019 Financial Results

Oct 30, 2019

Arcutis Announces Addition of Three Senior Biopharmaceutical Executives to Management Team

Oct 30, 2019

Alpine Immune Sciences Completes Enrollment of Phase I Study of ALPN-101 and Announces Third Quarter Conference Call

Oct 29, 2019

Passage Bio Appoints Richard Morris as Chief Financial Officer

Oct 29, 2019

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results

Oct 29, 2019

Harpoon Therapeutics Presents Preclinical Data For Hpn328, A Dll3-Targeting T Cell Engager, At Aacr-Nci-Eortc International Conference On Molecular Targets And Cancer Therapeutics

Oct 29, 2019

Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at 2019 ESGCT Annual Congress

Oct 28, 2019

ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 28, 2019

ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at AACR-NCI-EORTC Annual Conference

Oct 24, 2019

Compass Therapeutics to Present Preclinical Data on a Novel PD-1/PD-L1 Bispecific Antibody and from its Proprietary Innate Cell Engager Platform at the 2019 SITC Meeting

Oct 24, 2019

SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN)

Oct 24, 2019

Intellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)

Oct 24, 2019

Arcutis Biotherapeutics Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Phase 3 Program for ARQ-151 for Plaque Psoriasis

Oct 23, 2019

Arvinas presents a platform update, including initial data from the first two clinical trials of protac targeted protein degraders

Oct 23, 2019

Avera eCARE® Selects Tyto Care as an Enterprise Solution for Virtual Care

Oct 22, 2019

Compass Therapeutics Appoints Leading Immuno-Oncology Researchers to Its Immuno-Oncology Scientific Advisory Board

Oct 22, 2019

Harpoon therapeutics announces presentation on HPN328 at AACR-NCI-EORTC international conference on molecular targets and cancer therapeutics

Oct 21, 2019

Ascendis Pharma A/S Receives Orphan Designation for TransCon™ hGH for the Treatment of Pediatric Growth Hormone Deficiency in Europe

Oct 21, 2019

Arcutis Announces the Completion of $94.5 million Series C Financing

Oct 21, 2019

ReViral Announces Appointment of Alan Musso as Chief Financial Officer

Oct 21, 2019

Aerpio Pharmaceuticals Announces Review of Strategic Alternatives

Oct 18, 2019

Verrica Pharmaceuticals Announces Presentation of Positive Data from Clinical Trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology Conference

Oct 18, 2019

ESSA Announces Changes to its Board of Directors

Oct 18, 2019

Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers

Oct 17, 2019

Enyo pharma announces multiple EYP001 data presentations at AASLD conference

Oct 17, 2019

Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD

Oct 16, 2019

Natera Announces Pricing of Follow-On Offering

Oct 16, 2019

Novant Health and Tyto Care Partner to Provide Unique Digital Health Offerings

Oct 15, 2019

Principia Announces Positive Preliminary Data of PRN1008 For Immune Thrombocytopenia in Ongoing Phase 1/2 Trial

Oct 15, 2019

Terns pharmaceuticals to present postive preclinical data on fxr agonist TERN-101 at the liver meeting 2019

Oct 15, 2019

Principia Announces Proposed Public Offering of Common Stock

Oct 15, 2019

Principia Announces Pricing of Public Offering of Common Stock

Oct 10, 2019

Principia Announces Positive Preliminary Data of PRN1008 From Its Ongoing Phase 2 Part B Trial in Pemphigus

Oct 10, 2019

Aerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma

Oct 9, 2019

TigerConnect Recognized as One of the Best Places to Work in Healthcare for the Fifth Consecutive Year

Oct 9, 2019

Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies

Oct 9, 2019

Arcutis Announces Enrollment of Last Patient in Phase 2a Clinical Trial of ARQ-151 Cream as a Potential Topical Treatment for Atopic Dermatitis

Oct 9, 2019

Verrica Pharmaceuticals Appoints Eugene Scavola to the Position of Executive Vice President, Technical Operations

Oct 8, 2019

Prevail Therapeutics and Lonza Establish Strategic Collaboration to Develop and Manufacture Prevail's Novel AAV9 Gene Therapy Programs for Patients with Neurodegenerative Diseases

Oct 7, 2019

Verrica Pharmaceuticals Announces Leadership Team Update

Oct 5, 2019

Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society

Oct 3, 2019

Enyo pharma announces move to new corporate headquarters

Oct 2, 2019

resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019

Oct 2, 2019

NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer

Oct 2, 2019

Arvinas strengthens scientific advisory board with leaders in oncology and neurological disorders

Oct 2, 2019

Adicet Bio Raises $80M in Series B Financing

Oct 2, 2019

Graybug Vision Initiates Phase 2b (ALTISSIMO) Clinical Trial of GB-102 in Patients with Wet Age-Related Macular Degeneration

Oct 1, 2019

CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia

Oct 1, 2019

Constellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing Investors

Oct 1, 2019

Bayer and Arvinas unveil targeted protein degradataion joint venture, Oerth Bio

Oct 1, 2019

Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer

Sep 30, 2019

X4 Pharmaceuticals Reports Positive Data from Phase 2a Trial of Mavorixafor in Combination with Axitinib in Advanced Clear Cell Renal Cell Carcinoma Patients

Sep 30, 2019

Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor

Sep 30, 2019

Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO

Sep 30, 2019

Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including New Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients With X-Linked Myotubular Myopathy (XLMTM)

Sep 30, 2019

European Respiratory Society International Congress, Madrid 29 September 2019

Sep 28, 2019

ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress

Sep 27, 2019

Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical Association

Sep 26, 2019

Inspire Medical Systems, Inc. Announces Additional Draft Local Coverage Determinations Proposing Coverage of Inspire Therapy

Sep 26, 2019

Arbitration Decision Affirms Intellia Therapeutics’ Interpretation of Licensing Agreement with Caribou Biosciences on the CRISPR/Cas9 Technology

Sep 25, 2019

89bio Announces Dosing of First Patients in NASH Study and Issuance of Composition of Matter Patent

Sep 25, 2019

SI-BONE, Inc. Announces Publication of Five-Year Prospective Study Results on 103 Patients Treated with Triangular Titanium iFuse Implant System

Sep 24, 2019

European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue Sarcoma

Sep 24, 2019

Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise

Sep 24, 2019

Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring

Sep 23, 2019

Passage Bio Grows Management Team with Chief Medical Officer and General Counsel Appointments

Sep 23, 2019

Adicet Bio Appoints Francesco Galimi, M.D., Ph.D., SVP and Chief Medical Officer

Sep 23, 2019

X4 Pharmaceuticals Appoints William E. Aliski to Board of Directors

Sep 19, 2019

Prevail Therapeutics Announces Addition to Russell 2000®, 3000® and Microcap® Indexes

Sep 18, 2019

Graybug Vision Initiates Clinical Trial in Macular Edema Secondary to Diabetic Macular Edema or Retinal Vein Occlusion

Sep 18, 2019

scPharmaceuticals Inc. Provides FUROSCIX® Update and Announces Completion of $20.0 Million Term Loan Agreement

Sep 18, 2019

Arcutis, Inc.’s Development Program for Eczema

Sep 18, 2019

X4 Pharmaceuticals Appoints Renato Skerlj, Ph.D. as Senior Vice President of Research and Development

Sep 17, 2019

SpringWorks Therapeutics Announces Closing Of Initial Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional Shares

Sep 17, 2019

BELLUS Health Announces Exercise of Over-Allotment Option in Connection With Underwritten Public Offering of Common Shares

Sep 17, 2019

Edgewise Therapeutics Closes $50 Million Series B Financing

Sep 17, 2019

Xenon Announces Appointment of Shelley McCloskey as Senior Vice President, Human Resources

Sep 16, 2019

Verrica Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for VP-102 for the Treatment of Molluscum Contagiosum

Sep 13, 2019

Gemini Therapeutics Announces Leadership Appointment

Sep 13, 2019

Imara Submits Confidential Draft Registration Statement for Proposed Initial Public Offering

Sep 12, 2019

Tricida Launches Metabolic Acidosis Insights, an Online Educational Resource for the Healthcare Community

Sep 12, 2019

Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon™ CNP at International Skeletal Dysplasia Society Meeting

Sep 12, 2019

SpringWorks Therapeutics Announces Pricing Of Initial Public Offering

Sep 11, 2019

ObsEva announces new composition of its Executive Committee

Sep 11, 2019

Boost Epi-On™ Corneal Cross-Linking Data to Be Presented at the 37th Congress of the ESCRS

Sep 10, 2019

ORIC Pharmaceuticals Appoints Dominic Piscitelli as Chief Financial Officer

Sep 10, 2019

Prevail Therapeutics Provides Program Update on PR001 in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher Disease

Sep 9, 2019

Nabriva’s XENLETA™ (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S.

Sep 9, 2019

Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain

Sep 9, 2019

BELLUS Health Closes US$70 Million Public Offering of Common Shares in Canada and the United States

Sep 9, 2019

United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4

Sep 9, 2019

Natera Publishes Largest NIPT Outcomes Study Demonstrating Robust Clinical Performance Over a 4-year Period

Sep 9, 2019

Enyo Pharma Announces New CFO and Provides Clinical Pipelien Update

Sep 9, 2019

Passage Bio Announces New Gene Therapy Development Program for Patients with Charcot-Marie-Tooth Neuropathy Type 2A

Sep 9, 2019

Alector Initiates Phase 2 Trial of AL001 in Patients with Frontotemporal Dementia

Sep 6, 2019

Nabriva Therapeutics Earns $5 Million Milestone Payment under its License Agreement with Sinovant Sciences

Sep 5, 2019

Turning Point Therapeutics Announces Pricing of Public Offering of Common Stock

Sep 5, 2019

BELLUS Health Announces Pricing of US$70 Million Public Offering in Canada and the United States

Sep 4, 2019

Synlogic Presents Data from Phase 1/2a Study of SYNB1618 at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM)

Sep 4, 2019

Selecta Biosciences Appoints Brad Dahms as Chief Financial Officer

Sep 4, 2019

Passage Bio Closes $110 Million Series B Financing

Sep 4, 2019

Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO Departure

Sep 4, 2019

Tricida Announces Submission of New Drug Application for Veverimer for the Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease

Sep 3, 2019

Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium

Sep 3, 2019

SI-BONE, Inc. Announces Wellmark Blue Cross Blue Shield Establishes Positive Coverage for MIS SI Joint Fusion Using iFuse

Sep 3, 2019

Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib and Preclinical Data for TPX-0046, a Novel RET/SRC Inhibitor

Sep 3, 2019

Turning Point Therapeutics Announces Proposed Public Offering of Common Stock

Sep 3, 2019

ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF

Sep 3, 2019

BELLUS Health Announces the Launch of a US$60 Million Public Offering of Common Shares in Canada and the United States and the Filing of an Application to List Its Common Shares on Nasdaq

Aug 30, 2019

SpringWorks Therapeutics Appoints Alan Fuhrman to its Board of Directors

Aug 30, 2019

Principia Biopharma Appoints Shawn Tomasello to its Board of Directors

Aug 29, 2019

Inspire Medical Systems, Inc. Announces Additional Draft Local Coverage Determinations Proposing Coverage of Inspire Therapy

Aug 29, 2019

SpringWorks Therapeutics Receives Breakthrough Therapy Designation for Nirogacestat for the Treatment of Adult Patients with Progressive, Unresectable, Recurrent or Refractory Desmoid Tumors

Aug 28, 2019

Ascendis Pharma A/S Reports Second Quarter 2019 Financial Results

Aug 27, 2019

NeRRe Therapeutics Announces Publication of Positive Results in a Phase 2 Pilot Study of Orvepitant in Chronic Refractory Cough

Aug 27, 2019

Arvinas announces the initiation of patient dosing in a first-in-human phase 1 study of ARV-471, an estrogen receptor-targeting protac protein degrader

Aug 27, 2019

Pionyr Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages

Aug 27, 2019

ESSA Pharma Completes Public Offering and Concurrent Private Placement for Aggregate Gross Process of US$36 Million

Aug 27, 2019

Cyrus Biotechnology Offers CryoEM Services based on First-in-class, Peer-reviewed Rosetta Software Methods

Aug 27, 2019

Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients

Aug 26, 2019

BELLUS Health Strengthens Leadership Team with Appointment of Dr. Catherine Bonuccelli, MD as Chief Medical Officer

Aug 26, 2019

Inspire Medical Systems, Inc. Announces Draft Local Coverage Determinations Proposing Coverage of Inspire Therapy from Two Regional Medicare Administrators

Aug 23, 2019

ESSA Pharma Announces $36 Million Public Offering of Common Stock and Concurrent Private Placement

Aug 22, 2019

Medicare Issues Positive Draft Local Coverage Determination for Natera's Signatera� MRD Test in Colorectal Cancer

Aug 20, 2019

Graybug Vision Secures $80 million of Additional Funding to Advance its Potentially Transformative Retina and Glaucoma Clinical Programs

Aug 20, 2019

Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia

Aug 19, 2019

Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta™ (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP)

Aug 16, 2019

Nabriva Therapeutics Provides Update on the Planned Resubmission of the New Drug Application for Intravenous CONTEPO™ (fosfomycin) for Injection

Aug 15, 2019

BELLUS Health Announces Share Consolidation

Aug 15, 2019

Inspire Medical Systems, Inc. Announces Additional 17.7 Million Covered Lives with Seven New Coverage Policies

Aug 14, 2019

Prevail Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights

Aug 14, 2019

resTORbio Reports Second Quarter 2019 Financial Results and Corporate Update

Aug 13, 2019

Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Aug 13, 2019

Inspire Medical Systems, Inc. Announces New Brand Identity and Website to Better Reach Prospective Patients Struggling with Sleep Apnea

Aug 13, 2019

Alpine Immune Sciences Provides Pipeline Update and Reports Second Quarter 2019 Financial Results

Aug 13, 2019

Imara Expands Management Team and Strengthens Expertise Across Strategic Functions as it Advances IMR-687 for Sickle Cell Disease and Beta Thalassemia

Aug 13, 2019

Passage Bio Announces Launch of Natural History Study to Evaluate Patients with GM1 Gangliosidosis

Aug 12, 2019

Alector Announces the Addition of Kristine Yaffe, M.D., to the Board of Directors

Aug 12, 2019

Alector Reports Recent Business Highlights and Second Quarter 2019 Financial Results

Aug 8, 2019

Tricida Announces Second Quarter 2019 Financial Results

Aug 8, 2019

Selecta Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Aug 8, 2019

ORIC Pharmaceuticals Announces Completion of $55 Million Mezzanine Financing to Advance Pipeline of Novel Therapies Targeting Cancer Resistance

Aug 8, 2019

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results

Aug 8, 2019

89bio Initiates Phase 1b/2a Proof of Concept Clinical Trial of Investigational Therapy BIO89-100 for the Treatment of NASH

Aug 8, 2019

Synlogic Reports Second Quarter 2019 Financial Results and Provides Program Updates

Aug 8, 2019

Principia biopharma reports second quarter financial results

Aug 8, 2019

Aerpio Reports Second Quarter 2019 Financial Results and Provides Business Update

Aug 8, 2019

Kala Pharmaceuticals Receives FDA Complete Response Letter for KPI-121 0.25% NDA and Plans To Repond with Data from Stride 3 Trial

Aug 8, 2019

BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2019

Aug 8, 2019

Nabriva Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

Aug 7, 2019

Avedro, Inc. Announces Second Quarter 2019 Financial Results

Aug 7, 2019

Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2019 Financial Results

Aug 7, 2019

ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC

Aug 7, 2019

ObsEva Reports Second Quarter 2019 Financial Results

Aug 7, 2019

Selecta Biosciences Combines ImmTOR™ Platform with AskBio’s Industry-Leading Gene Therapy Platform in Strategic Partnership

Aug 7, 2019

scPharmaceuticals Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update

Aug 7, 2019

Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities

Aug 7, 2019

Verrica Pharmaceuticals Reports Second Quarter 2019 Financial Results

Aug 7, 2019

Glaukos and Avedro Announce Definitive Acquisition Agreement

Aug 6, 2019

Xenon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Aug 6, 2019

Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights

Aug 6, 2019

Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Aug 6, 2019

Kala Pharmaceuticals Reports Second Quarter 2019 Financial Results

Aug 6, 2019

SI-BONE, Inc. Reports Second Quarter 2019 Financial Results

Aug 6, 2019

Turning Point Therapeutics Reports Second Quarter 2019 Financial and Operational Results

Aug 6, 2019

Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019

Aug 6, 2019

Inspire Medical Systems, Inc. Announces Second Quarter 2019 Financial Results and Increases 2019 Outlook

Aug 5, 2019

Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD

Aug 5, 2019

Arvinas Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Aug 5, 2019

Harpoon Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Aug 1, 2019

Intellia Therapeutics Announces Second Quarter 2019 Financial Results and Company Update

Aug 1, 2019

Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update

Aug 1, 2019

Compass Therapeutics Appoints Julie Sunderland to Board of Directors

Aug 1, 2019

New Executive Team Announced at Adaptimmune

Aug 1, 2019

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial Results

Aug 1, 2019

CTI BioPharma Reports Second Quarter 2019 Financial Results

Aug 1, 2019

Synthorx Reports Second Quarter Financial Results

Jul 31, 2019

Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid Tumors

Jul 30, 2019

TransMedics Announces Successful Long Distance Retrieval and Transplantation of Donor Lungs from Hawaii Using Organ Care System (OCS�)

Jul 30, 2019

Foamix Announces $64 Million Capital Financing Investment by Perceptive Advisors and OrbiMed

Jul 30, 2019

Principia announces update to ongoing Phase 2 clinical trial in patients with ITP

Jul 30, 2019

X4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM Syndrome

Jul 30, 2019

BELLUS Health Announces First Patient Enrolled in Phase 2 Study of BLU-5937 for the Treatment of Refractory Chronic Cough & Pursuit of Second Indication in Chronic Pruritus

Jul 30, 2019

NeuroPace Appoints Mark Saxton as Vice President of Sales

Jul 29, 2019

Rhythm Pharmaceuticals Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for Setmelanotide for the Treatment of Bardet-Biedl Syndrome

Jul 29, 2019

Arvinas appoints Ronald Peck, M.D as Chief Medical Officer

Jul 29, 2019

Turning Point Therapeutics Appoints Biotechnology Investment Banker Yi Larson as Executive Vice President and Chief Financial Officer

Jul 29, 2019

Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH Congenital Hyperinsulism

Jul 29, 2019

Rhythm Pharmaceuticals Reports Second Quarter 2019 Financial Results

Jul 26, 2019

ObsEva SA Reports Positive Feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022

Jul 25, 2019

Inspire Medical Systems, Inc. Announces Changes to its Board of Directors

Jul 25, 2019

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2019 Earnings and Company Update

Jul 25, 2019

Turning Point Therapeutics Names Carol Gallagher, Pharm.D. to its Board of Directors

Jul 25, 2019

Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS

Jul 25, 2019

Passage Bio Expands Executive Management Team

Jul 25, 2019

Arvinas strengthens board of directors with addition of Leslie Norwalk

Jul 24, 2019

Health Catalyst Announces Pricing of Initial Public Offering

Jul 24, 2019

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2019 Financial Results on August 1, 2019

Jul 24, 2019

Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707

Jul 24, 2019

Rhythm Pharmaceuticals Announces Appointment of Stuart Arbuckle to its Board of Directors

Jul 24, 2019

NeuroPace Announces Michael Favet as CEO

Jul 24, 2019

Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency

Jul 23, 2019

resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness

Jul 23, 2019

Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression

Jul 22, 2019

Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center

Jul 22, 2019

Arcutis, Inc. Announces Positive Top Line Results for Phase 2b Clinical Trial Evaluating ARQ-151 as a Potential Topical Treatment for Plaque Psoriasis

Jul 19, 2019

Realm Therapeutics plc Update on Company’s Nasdaq Listing

Jul 18, 2019

Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for Initiation of a Global Phase 2 Trial for TransCon™ CNP in Children with Achondroplasia

Jul 18, 2019

CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis

Jul 18, 2019

Augmedix, powered by Glass, accelerates scaling efforts with the nation’s leading healthcare systems

Jul 18, 2019

ViewRay Announces Conference Call and Webcast of Second Quarter 2019 Financial Results to be Held After Market on August 8, 2019

Jul 18, 2019

Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE?A4 to Enhance Antitumor Responses

Jul 17, 2019

X4 Pharmaceuticals and Abbisko Therapeutics Enter into Oncology Development and Commercialization Agreement for Mavorixafor in Greater China

Jul 17, 2019

ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban

Jul 17, 2019

SI-BONE To Report Second Quarter 2019 Financial Results on August 6, 2019

Jul 17, 2019

ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programs

Jul 17, 2019

ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids

Jul 17, 2019

Alector Announces Data from On-going Phase 1b Trial Demonstrating that AL001 Reverses Progranulin Deficiency in Frontotemporal Dementia Patients

Jul 17, 2019

Rhythm Pharmaceuticals Launches Free Genetic Testing Program for Rare Genetic Disorders of Obesity

Jul 16, 2019

ViewRay Announces Appointment of Dr. Gail Wilensky to its Board of Directors

Jul 16, 2019

SCPHARMACEUTICALS INC. PROVIDES REGULATORY UPDATE ON FUROSCIX®

Jul 16, 2019

Crinetics Pharmaceuticals appoints Stephanie Okey to Board of Directors

Jul 15, 2019

Selecta Biosciences Appoints Alison Schecter, M.D., as Chief Medical Officer

Jul 15, 2019

Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development

Jul 10, 2019

Pionyr Immunotherapeutics and ProBioGen Initiate a Second Immuno-Oncology Contract Development and Manufacturing Project

Jul 10, 2019

NIH Study to Utilize NeuroPace RNS® System for Research on the Brain’s Reward System

Jul 10, 2019

Acutus Medical Announces Addition of Scott Huennekens as Executive Chairman of the Board

Jul 10, 2019

Passage Bio Announces New Dedicated Gene Therapy Manufacturing Suite

Jul 9, 2019

Inspire Medical Systems, Inc. to Report Second Quarter 2019 Financial Results on August 6, 2019

Jul 9, 2019

ORIC Pharmaceuticals Appoints Lori Friedman, PhD, as Chief Scientific Officer

Jul 9, 2019

Inspire Medical Systems, Inc. Announces UnitedHealthcare Coverage for Inspire Therapy for the Treatment of Obstructive Sleep Apnea

Jul 8, 2019

Compass Therapeutics Announces First Patient Dosed in Phase 1 Trial of CTX-471

Jun 27, 2019

SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma

Jun 27, 2019

SI-BONE’s iFuse Implant System Surpasses 40,000 Procedures

Jun 27, 2019

Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer

Jun 26, 2019

Intellia Therapeutics' Statement on Recent U.S. Patent and Trademark Office Actions Relating to Key CRISPR/Cas9 Genome Editing Technology

Jun 26, 2019

X4 Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Mavorixafor for the Treatment of WHIM Syndrome

Jun 26, 2019

Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts

Jun 25, 2019

Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine

Jun 25, 2019

Tricida Announces Publication of Positive Long-Term Phase 3 Clinical Trial Results of Veverimer (TRC101) in The Lancet

Jun 24, 2019

Realm Shareholders Approve Scheme of Arrangement for Acquisition by ESSA Pharma Inc. at Court Meeting

Jun 24, 2019

Nabriva Therapeutics Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application for Lefamulin

Jun 20, 2019

Turning Point Therapeutics Initiates Phase 2 Registrational Portion of TRIDENT-1 Clinical Study

Jun 20, 2019

Acutus Medical Announces $170 Million Financing

Jun 20, 2019

Selecta Biosciences Announces Appointment of Scott D. Myers to Board of Directors

Jun 19, 2019

ObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA Meeting

Jun 19, 2019

Rhythm Pharmaceuticals Announces Election of Jennifer Good to its Board of Directors

Jun 19, 2019

Prevail Therapeutics Announces Pricing of Initial Public Offering

Jun 19, 2019

Nabriva Therapeutics Submits Type A Meeting Request to FDA for Intravenous CONTEPO™ (fosfomycin) for injection

Jun 18, 2019

Imara Presented Positive, Interim Phase 2a Data on IMR-687 for the Treatment of Sickle Cell Disease at the 24th Congress of the European Hematology Association

Jun 18, 2019

BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor

Jun 17, 2019

Invitae to Acquire Singular Bio to Help Increase Access to Genetic Screening in Early Pregnancy

Jun 17, 2019

SI-BONE Announces the Addition of Mark Foley and Heyward Donigan to the Board of Directors

Jun 13, 2019

Terns Pharmaceuticals Initiates a Phase 1 Clinical Trial of Tern-101

Jun 13, 2019

PMV Pharma Appoints Deepika Jalota, Pharm.D. as Senior Vice President and Head of Regulatory Affairs

Jun 12, 2019

Selecta Biosciences Presents Full Data from Phase 2 Trial of SEL-212 for Chronic Refractory Gout at EULAR 2019

Jun 12, 2019

Constellation Pharmaceuticals Presentation Highlights Enhanced EZH2 Target Engagement, Leading to Second-Generation EZH2 Inhibitor CPI-0209

Jun 12, 2019

Invitae Announces ID YOUR IRD Program to Expand Access to Genetic Testing for Inherited Retinal Disorders

Jun 12, 2019

Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic™ Medicines

Jun 12, 2019

X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease

Jun 11, 2019

ReViral Appoints Alex C. Sapir as Chief Executive Officer

Jun 11, 2019

Principia Biopharma Appoints Patrick Machado To Board of Directors

Jun 10, 2019

Aerpio Initiates Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma

Jun 7, 2019

Nerre Therapeutics Announces Positive Findings From Phase 2B Study With Orvepitant In Chronic Cough

Jun 5, 2019

HLS Therapeutics Announces Closing of $50 Million Bought Deal Offering

Jun 4, 2019

ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes

Jun 4, 2019

Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD

Jun 4, 2019

Prevail Therapeutics Announces IND Active for Phase 1/2 Trial of its Gene Therapy PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations

Jun 3, 2019

SpringWorks Therapeutics Announces FDA Fast Track Designation for PD-0325901 for the Treatment of a Severe Form of Neurofibromatosis Type 1

Jun 3, 2019

Invitae introduces new service to make it easier for consumers to receive the medical genetic testing that experts trust

Jun 3, 2019

Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency

Jun 3, 2019

Interim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis Patients

Jun 3, 2019

TransMedics Announces the Second FDA PMA Approval for its OCS Lung System, Allowing Access to a Larger Pool of Donor Lungs that are Currently Seldomly Utilized for Transplantation Due to Limitations of Cold Storage

Jun 3, 2019

ARQ-151 Atopic Dermatitis P2a Trial Initiated

Jun 3, 2019

Alpine Immune Sciences Appoints Biopharma Veteran Wayne Gombotz as Chief Technology Officer

Jun 2, 2019

Corvus Pharmaceuticals Presents Initial CPI-006 Phase 1/1b Clinical Data at 2019 ASCO Annual Meeting

May 31, 2019

Research from Invitae Demonstrates the Importance of Germline Multigene Panel Testing in Guiding Therapy for Expanding Groups of Cancer Patients

May 31, 2019

Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib in Advanced ROS1+ Non-Small Cell Lung Cancer

May 30, 2019

Passage Bio Announces Third Gene Therapy Development Program in Krabbe Disease and Supports Million Dreams Fundraising Gala

May 30, 2019

Ascendis Pharma A/S Reports First Quarter 2019 Financial Results

May 29, 2019

Imara Announces FDA Fast Track Designation for IMR-687 for the Treatment of Sickle Cell Disease

May 29, 2019

Audentes Therapeutics Announces Changes to Senior Management Team

May 29, 2019

Cyrus Biotechnology Integrates DNA/RNA support into its Rosetta-based Protein Design Platform

May 22, 2019

World's First MRIdian Center Treats 1,000th Patient with MRI-Guided Radiation Therapy

May 22, 2019

89bio Reports Positive Top-line Data from Phase 1 Single-Ascending Dose Clinical Trial of BIO89-100, an Investigational Medicine for NASH

May 22, 2019

Tyto Care Joins Epic App Orchard to Offer One-of-a-kind Integrated Telehealth Service to Patients and Health Providers

May 22, 2019

Synlogic Announces Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

May 21, 2019

BELLUS Health Presents Phase 1 Data for BLU-5937, its Lead Product Candidate for the Treatment of Refractory Chronic Cough, at the American Thoracic Society International Conference

May 21, 2019

Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline

May 21, 2019

Crinetics Pharmaceuticals Initiates Phase 1 Study Of CRN01941 For The Treatment Of Neuroendocrine Tumors

May 20, 2019

SpringWorks Therapeutics Announces Initiation of Phase 3 Trial (DeFi) of Nirogacestat in Adult Patients with Desmoid Tumors

May 20, 2019

Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference

May 20, 2019

Principia Presents Phase 1 Data Of Prn1371 In Patients With Metastatic Bladder Cancer

May 20, 2019

resTORbio Presents Additional Phase 2b Data at the American Thoracic Society International Conference for RTB101 as a Potential Immunotherapy to Reduce the Incidence of Respiratory Tract Infections in Patients 65 Years of Age and Older with Asthma

May 20, 2019

Ascendis Pharma A/S Announces Preliminary Data from Single Arm Phase 3 fliGHt Trial Demonstrated TransCon™ hGH was Safe and Well-Tolerated in Pediatric Subjects Previously Treated with Daily Growth Hormone

May 16, 2019

Constellation Pharmaceuticals Provides Interim Update of Data for CPI-0610 in ASCO and EHA Abstracts

May 16, 2019

Prevail Therapeutics Announces Executive Team Promotion and Appointments to Board of Directors

May 16, 2019

Agreement Reached for ESSA Pharma to Acquire Realm Therapeutics

May 15, 2019

X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia

May 15, 2019

Turning Point Therapeutics Announces FDA Clearance Of Investigational New Drug Application For TPX-0022, A Novel MET/CSF1R/SRC Inhibitor

May 15, 2019

Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products

May 15, 2019

resTORbio Reports First Quarter 2019 Financial Results and Corporate Update

May 15, 2019

TigerConnect Names Sarah Shillington SVP of Client Success

May 14, 2019

resTORbio Appoints Lloyd Klickstein, M.D., Ph.D., as Chief Scientific Officer

May 14, 2019

Turning Point Therapeutics Names Biotech Veteran Patrick Machado, J.D. To Its Board Of Directors.

May 14, 2019

Principia Biopharma Announces First Patient Dosed In Sanofi’s Phase 2b Trial Of SAR442168 In Multiple Sclerosis, Triggering $30 Million Milestone

May 14, 2019

ReViral to Present Data Showing Absence of Clinical Resistance in Volunteers Infected with RSV then Treated with Sisunatovir (RV521)

May 13, 2019

ORIC Pharmaceuticals Announces Initiation of Phase 1b Study with ORIC-101 in Patients with Cancer

May 13, 2019

Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results And Provides Corporate Update

May 13, 2019

Alector Reports Recent Business Highlights and First Quarter 2019 Financial Results

May 10, 2019

Nabriva Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

May 9, 2019

resTORbio Announces Initiation of Phase 3 Clinical Program of RTB101 in Clinically Symptomatic Respiratory Illness

May 9, 2019

ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe

May 9, 2019

Harpoon Therapeutics Reports First Quarter 2019 Financial Results And Provides Corporate Update

May 9, 2019

Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2019 Financial Results

May 9, 2019

ObsEva Reports First Quarter 2019 Financial Results

May 9, 2019

Selecta Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update

May 9, 2019

Avedro, Inc. Announces First Quarter 2019 Financial Results

May 9, 2019

NeuroPace Shares Positive Data from Studies of the RNS System at the American Academy of Neurology 2019 Annual Meeting

May 9, 2019

Aerpio Reports First Quarter 2019 Financial Results and Provides Business Update

May 9, 2019

Synlogic Reports First Quarter 2019 Financial Results and Provides Business Update

May 9, 2019

Kala Pharmaceuticals Reports First Quarter 2019 Financial Results

May 9, 2019

Acutus Medical Expands AFib Offerings; Announces Strategic Acquisition and New Partnerships in Monitoring and Therapy

May 8, 2019

Adimab Announces Antibody Discovery Platform Transfer with Takeda

May 8, 2019

scPharmaceuticals Inc. Reports First Quarter 2019 Financial Results and Provides Business Update

May 8, 2019

Constellation Pharmaceuticals Announces First-Quarter 2019 Financial Results

May 8, 2019

Nabriva Therapeutics Announces Submission of Marketing Authorization Application for Lefamulin to Treat Community-Acquired Pneumonia in Adults by European Medicines Agency

May 8, 2019

Adimab Expands Research Agreement with Regeneron

May 8, 2019

Adimab Announces Multi-Target Expansion for the Discovery of Antibodies with Another Global Pharma Partner

May 8, 2019

SI-BONE, Inc. Reports First Quarter 2019 Financial Results

May 8, 2019

BELLUS Health Provides Update on Its Chronic Cough Drug Candidate BLU-5937 and Reports Financial and Operating Results for the First Quarter Ended March 31, 2019

May 8, 2019

Tricida Announces First Quarter 2019 Financial Results

May 7, 2019

Invitae Reports 47% Growth in Quarterly Revenue and Volume Year-Over-Year

May 7, 2019

Principia Biopharma Reports First Quarter Financial Results

May 7, 2019

Peloton Therapeutics Appoints Timothy P. Coughlin and Thilo Schroeder, Ph.D. to its Board of Directors

May 7, 2019

Kyn Therapeutics Strengthens Leadership Team with Key Appointments

May 7, 2019

Verrica Pharmaceuticals Reports First Quarter 2019 Financial Results

May 7, 2019

Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

May 7, 2019

Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019

May 7, 2019

Signatera� Blood Test Detects Bladder Cancer Relapse Up to Eight Months Earlier Than Current Clinical Standards

May 7, 2019

Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights

May 7, 2019

Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials

May 7, 2019

Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

May 6, 2019

TransMedics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

May 6, 2019

Inspire Medical Systems, Inc. Announces Additional 11.2 Million Covered Lives with New Blue Cross Blue Shield Coverage Policies

May 6, 2019

Adaptimmune Reports First Quarter 2019 Financial Results

May 6, 2019

Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors

May 6, 2019

Alector Announces First Alzheimer’s Disease Patient Dosed in Phase 1b Study of AL002

May 6, 2019

Turning Point Therapeutics And Almac Diagnostic Services Announce Approval Of An Investigational Device Exemption For The Companion Diagnostic Assay To The Registrational TRIDENT-1 Clinical Study

May 3, 2019

Rhythm Pharmaceuticals Reports First Quarter 2019 Financial Results

May 2, 2019

Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update

May 2, 2019

Aerpio Pharmaceuticals Presents Data Showing Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, to Lower Intra-ocular Pressure in Human Subjects

May 2, 2019

CTI BioPharma Reports First Quarter 2019 Financial Results

May 2, 2019

ViewRay Reports First Quarter 2019 Results

May 1, 2019

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results

May 1, 2019

Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy

May 1, 2019

Avedro Completes Enrollment in Pivotal U.S. Phase 3 Epi-On Corneal Cross-Linking Clinical Trial for Progressive Keratoconus

Apr 30, 2019

Synthorx Reports First Quarter Financial Results

Apr 30, 2019

Arcutis, Inc. Announces Board of Directors

Apr 30, 2019

Adicet Bio Appoints Anil Singhal Chief Executive Officer

Apr 30, 2019

Synlogic Presents Data Describing a Solid Oral Formulation Process for Synthetic Biotic™ aMedicine SYNB1618 for the Treatment of PKU at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Apr 30, 2019

Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for Intravenous CONTEPO™ (fosfomycin) for injection

Apr 29, 2019

Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy

Apr 29, 2019

ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF

Apr 26, 2019

Acutus Medical’s New Contact Mapping Software Receives CE Mark

Apr 25, 2019

TELA Bio® Appoints Kurt Azarbarzin Chairman of Board of Directors

Apr 24, 2019

Ascendis Pharma A/S Announces Presentations Related to Rare Disease Endocrinology Pipeline at Upcoming Medical Conferences

Apr 24, 2019

X4 Pharmaceuticals Appoints E. Lynne Kelley, M.D. as Chief Medical Officer

Apr 23, 2019

Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility

Apr 22, 2019

Turning Point Therapeutics Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares

Apr 18, 2019

Alpine Immune Science Appoints Stanford Peng to President and Head of Research and Development

Apr 18, 2019

ViewRay Partners with Leading Canadian Distributor to Bring MRI-guided Radiation Therapy to Canada

Apr 18, 2019

Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T Cell Engager (HPN536) in Phase 1/2A Clinical Trial for Ovarian and Other Solid Tumor Cancers

Apr 18, 2019

Principia Bipharma Appoints Shao-Lee Lin Md PhD to Board of Directors

Apr 18, 2019

TELA Bio® Announces 510(k) Clearance for Restella™ Reconstructive BioScaffolds for Reconstructive Surgery

Apr 17, 2019

ViewRay Partners with Largest Independent Distributor in Australia and New Zealand to Bring Benefits of MRI-Guided Radiation Therapy to the Region

Apr 17, 2019

Alector Announces First Frontotemporal Dementia Patient Dosed in Phase 1b Study of AL001

Apr 16, 2019

Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting

Apr 16, 2019

Turning Point Therapeutics Announces Pricing Of Initial Public Offering

Apr 16, 2019

Inspire Medical Systems, Inc. Announces the 5,000th Patient to Receive Inspire Therapy

Apr 15, 2019

SI-BONE, Inc. Announces FDA Clearance of iFuse Bedrock™ Novel Spinopelvic Fixation Technology

Apr 12, 2019

X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants

Apr 11, 2019

ViewRay Announces Publication of Retrospective Study on MR-guided Radiation Treatment for Locally Advanced Pancreatic Cancer

Apr 11, 2019

X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class A Warrants

Apr 11, 2019

Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.

Apr 10, 2019

Imara Appoints Chief Financial & Chief Operating Officer

Apr 10, 2019

Realm Therapeutics Announces 2018 Annual Report Available and Form 20-F Filing

Apr 9, 2019

Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine

Apr 9, 2019

Peloton Therapeutics Announces Completion of Enrollment in Phase 2 Trial of PT2977 for Treatment of von Hippel-Lindau Disease-associated Renal Cell Carcinoma

Apr 9, 2019

Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A.

Apr 9, 2019

Synlogic Appoints Scott Plevy M.D. as Chief Scientific Officer

Apr 8, 2019

Tricida Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Apr 8, 2019

Inspire Medical Systems, Inc. Announces Three New Positive Coverage Policies Issued by Blue Cross Blue Shield Plans

Apr 8, 2019

Turning Point Therapeutics Appoints Annette North As Executive Vice President And General Counsel

Apr 8, 2019

https://www.reviral.co.uk/news/45/48/ReViral-Announces-Grant-of-Key-US-Composition-of-Matter-Patent-For-Their-Respiratory-Syncytial-Virus-inhibitor-programme.html

Apr 8, 2019

Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy

Apr 7, 2019

Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders

Apr 5, 2019

Avedro Reaches Reimbursement Milestone for Its FDA-Approved Procedure for Progressive Keratoconus

Apr 5, 2019

Realm Therapeutics Announces Receipt of Nasdaq Listing Determination and Requests Hearing

Apr 4, 2019

Grant of Options and RSUs and PDMR Dealings

Apr 3, 2019

BELLUS Health Announces Clearance of U.S. IND for BLU-5937 Phase 2 Study in Chronic Cough Patients

Apr 3, 2019

Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019

Apr 3, 2019

Ascendis Pharma A/S Reports Full Year 2018 Financial Results

Apr 3, 2019

Tricida Announces Pricing of Public Offering of Common Stock

Apr 3, 2019

Sonendo® to Launch the GentleWave® System in Canada at AAE 2019

Apr 2, 2019

resTORbio Announces Initiation of Phase 1b/2a Trial of RTB101 in Parkinson’s Disease

Apr 2, 2019

ORIC Pharmaceuticals Presents Evidence of Glucocorticoid Receptor-Medicated Cancer Treatment Resistance at the AACR Annual Meeting

Apr 2, 2019

X4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of Directors

Apr 2, 2019

Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting

Apr 1, 2019

Tricida Announces Proposed Public Offering of Common Stock

Apr 1, 2019

SpringWorks Therapeutics Completes $125 Million Series B Financing

Apr 1, 2019

Sierra Reports Late-Breaking Preclinical Data for SRA737 Presented at AACR 2019

Apr 1, 2019

Happy April 1! Announcing Cyrus ROSVAC-4!

Apr 1, 2019

Turning Point Therapeutics’ Kinase Inhibitors Show High Potency Against Targeted Oncogene Drivers And Their Mutations

Apr 1, 2019

X4 Pharmaceuticals Provides Business and Clinical Development Update

Apr 1, 2019

Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Thomas P. Soloway to Executive Vice President and Chief Financial Officer

Apr 1, 2019

Fusion Pharmaceuticals Raises $105 Million In Oversubscribed Series B Financing

Apr 1, 2019

Constellation Pharmaceuticals Presents Results from Phase 1b Portion of ProSTAR Clinical Trial of CPI-1205 at AACR Meeting

Apr 1, 2019

Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting

Apr 1, 2019

Alector Initiates Phase 1 Trial of AL003 for the Treatment of Patients with Alzheimer’s Disease

Apr 1, 2019

Peloton Therapeutics Announces Clinical Data Update for PT2977 at European International Kidney Cancer Symposium

Mar 29, 2019

Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic Refractory Gout and Strengthens Management Team

Mar 28, 2019

Rhythm Pharmaceuticals Announces Promising Clinical Data in MC4R Pathway Heterozygous Obesity and Strategy for Further Development

Mar 28, 2019

Tricida Announces $200 Million Debt Facility With Hercules Capital

Mar 28, 2019

Tricida Announces Fourth Quarter and Full-Year 2018 Financial Results

Mar 28, 2019

Tricida Announces Positive Results From Long-Term Clinical Trial of TRC101 in Patients With CKD and Metabolic Acidosis

Mar 27, 2019

Imara Appoints Chief Medical Officer

Mar 26, 2019

Alector Reports Recent Business Highlights and Fourth Quarter and Full Year 2018 Financial Results

Mar 25, 2019

Turning Point Therapeutics Appoints Jim Mazzola to Lead Corporate Communication and Investor Relations

Mar 25, 2019

Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life

Mar 24, 2019

Ascendis Pharma Announces Phase 3 heiGHt Trial Demonstrated Superior Efficacy and Comparable Safety and Tolerability of TransCon™ hGH to a Daily Growth Hormone

Mar 22, 2019

resTORbio, Inc. Announces Closing Public Offering of Common Stock

Mar 22, 2019

2018 Annual Report and Accounts and Notice of AGM

Mar 21, 2019

Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director

Mar 21, 2019

Sonendo® Announces Three Key Hires

Mar 21, 2019

Avedro, Inc. Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Full Year 2019 Financial Outlook

Mar 21, 2019

scPharmaceuticals Inc. Reports Fourth Quarter and Year Ended 2018 Financial Results and Provides Business Update

Mar 21, 2019

Turning Point Therapeutics Files Registration Statement for Proposed Initial Public Offering

Mar 19, 2019

Principia Biopharma Reports Fourth Quarter and Full Year 2018 Financial Results

Mar 19, 2019

Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly

Mar 18, 2019

resTORbio Reports Fourth Quarter and Full Year 2018 Financial Results

Mar 18, 2019

Imara Closes a $63MM Series B Cross-Over Financing

Mar 18, 2019

Aerpio Pharmaceuticals Announces Results From TIME-2b Study of AKB-9778 in Diabetic Retinopathy

Mar 18, 2019

Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2018 Financial Results

Mar 18, 2019

resTORbio Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Global Phase 3 Program for RTB101

Mar 18, 2019

Crinetics Pharmaceuticals Appoints Gina Ford, RPH, MBA, as Vice President, Corporate Strategy and Commercial Planning

Mar 17, 2019

Prevail Therapeutics Secures $50 Million in Series B Financing to Advance Pipeline of Gene Therapies for Neurodegenerative Diseases

Mar 15, 2019

Selecta Biosciences Announces Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update

Mar 15, 2019

Stereotaxis and Acutus Medical Combine Robotic Precision and High-Resolution Imaging to Treat Arrhythmias in First Integrated Procedures

Mar 14, 2019

Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019

Mar 14, 2019

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

Mar 14, 2019

Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2018 Financial Results

Mar 14, 2019

ViewRay Reports Fourth Quarter and Full Year 2018 Results

Mar 13, 2019

X4 Pharmaceuticals Completes Merger with Arsanis

Mar 13, 2019

ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019

Mar 13, 2019

Avedro, Inc. Announces Appointment of Patrick B. Jacques as Vice President of Sales

Mar 13, 2019

Crinetics Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Corporate Update

Mar 13, 2019

CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights

Mar 12, 2019

Nabriva Therapeutics Reports 2018 Financial Results and Recent Corporate Highlights

Mar 12, 2019

Synlogic Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

Mar 11, 2019

Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results

Mar 11, 2019

Tricida Announces Publication of Positive TRC101 Pivotal Trial Results in The Lancet

Mar 11, 2019

TELA Bio® Announces Multiple Presentations at American Hernia Society Annual Meeting in Las Vegas

Mar 11, 2019

Principia Biopharma Reacquires Rights to Oral Immunoproteasome Program

Mar 11, 2019

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

Mar 8, 2019

Sublimity Therapeutics to Present Positive Data for Ulcerative Colitis Drug Candidate

Mar 8, 2019

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

Mar 7, 2019

Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

Mar 7, 2019

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights

Mar 7, 2019

SI-BONE, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results

Mar 7, 2019

Verrica Reports Fourth Quarter and Full Year 2018 Financial Results

Mar 6, 2019

Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update

Mar 6, 2019

SI-BONE, Inc. Announces Journal of Bone and Joint Surgery (JBJS) Publishes 2-Year Results from iMIA, a European Multicenter Randomized Controlled Trial (RCT) of SI Joint Fusion with iFuse Implant System® vs Conservative Care

Mar 6, 2019

Synlogic Announces Achievement of Milestone in Collaboration to Develop Synthetic Biotic™ Medicines to Treat Inflammatory Bowel Disease

Mar 6, 2019

Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy

Mar 6, 2019

Invitae Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock

Mar 5, 2019

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

Mar 5, 2019

ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business Update

Mar 5, 2019

Cyrus Biotechnology Announces Release of Antibody Structure Prediction Software for Biologics Drug Development and Discovery

Mar 5, 2019

Aerpio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

Mar 4, 2019

Fusion Pharmaceuticals Announces Appointment Of John J. Crowley As Chief Financial Officer

Mar 4, 2019

Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD

Mar 4, 2019

NextCure and Yale Publish Nature Medicine Paper Detailing Novel Immunomedicine Target Siglec-15

Mar 4, 2019

Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency

Mar 4, 2019

ORIC Pharmaceuticals Appoints Edna Chow Maneval, PhD, as Senior Vice President of Clinical Development

Mar 4, 2019

Constellation Pharmaceuticals Appoints Jessica Christo as Chief Product Development Officer

Mar 4, 2019

Inspire Medical Systems, Inc. Announces Five New Positive Coverage Policies Issued by Blue Cross Blue Shield Plans

Mar 4, 2019

Invitae Announces Proposed Public Offering of Common Stock

Mar 2, 2019

Verrica Pharmaceuticals Presents Positive Results from Two Phase 3 Clinical Trials of VP-102 in Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Meeting

Mar 2, 2019

Principia Biopharma Announces Positive Data From Phase 2 Pemphigus Vulgaris Trial At 2019 American Academy Of Dermatology Annual Meeting In Late-Breaking Presentation

Mar 1, 2019

Principia Biopharma Presents Phase 1 Clinical Data From CNS Penetrating BTK Inhibitor Candidate PRN2246/SAR442168 at ACTRIMS 2019

Feb 28, 2019

Audentes Therapeutics Recognizes Rare Disease Day by Launching """"Be Bold for Courageous Patients"""" Program to Support Patients Living with Rare Diseases

Feb 28, 2019

Sierra Oncology Reports 2018 Year End Results

Feb 28, 2019

Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for Achondroplasia

Feb 27, 2019

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results

Feb 27, 2019

Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update

Feb 27, 2019

Sierra Oncology Announces Late-Breaking Oral and Poster Presentations at AACR 2019 for SRA737 and SRA141 Preclinical Data

Feb 27, 2019

CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update

Feb 26, 2019

Marinus Announces Leadership Transition

Feb 26, 2019

Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update

Feb 26, 2019

ReViral Ltd Appoints Seth Hetherington as Chief Medical Officer as it Prepares its Lead RSV Candidate to Enter Pediatric Phase IIa Clinical Trials

Feb 26, 2019

Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2018 Financial Results

Feb 25, 2019

Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio

Feb 22, 2019

Kala Pharmaceuticals Reports Inducement Grand Under NASDAQ Listing Rule 5635©(4)

Feb 21, 2019

ViewRay Announces FDA 510(k) Clearance for Advancements in MRI and Functional Imaging Technologies for MRIdian MRI-Guided Radiation Therapy System

Feb 21, 2019

BELLUS Health Presents 2018 Highlights and 2019 Corporate Plan

Feb 20, 2019

Peloton Therapeutics Secures $150 Million in Series E Financing

Feb 20, 2019

Constellation Pharmaceuticals Announces Appointment to Board of Directors

Feb 19, 2019

Alpine Immune Sciences Presents Preclinical ALPN-101 GvHD Data at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR (TCT Meetings)

Feb 19, 2019

Modis Therapeutics Announces that MT1621 Receives Breakthrough Therapy Designation from FDA For the Treatment of TK2 Deficiency

Feb 19, 2019

Invitae More Than Doubles Annual Volume and Revenue Year-Over-Year, Delivering 117% in Revenue Growth Driven by 102% Growth in Volume in 2018

Feb 19, 2019

Nabriva Therapeutics Announces Acceptance of New Drug Applications by the FDA for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults

Feb 13, 2019

Avedro Announces Pricing of Initial Public Offering

Feb 12, 2019

Synlogic Appoints Patricia N. Hurter, Ph.D. to Board of Directors

Feb 12, 2019

NeuroPace Announces New Category I CPT Code from AMA for Electrocorticography from an Implanted Brain Neurostimulator

Feb 12, 2019

Invitae Launches Non-Invasive Prenatal Screening (NIPS), Offering In-Depth Genetic Information in Early Pregnancy

Feb 11, 2019

Ascendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with Hypoparathyroidism

Feb 11, 2019

Clementia Granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans Progressiva

Feb 11, 2019

Alpine Immune Sciences Announces First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program ALPN-101

Feb 11, 2019

CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®

Feb 7, 2019

Sublimity Therapeutics Presents Encouraging New Efficacy Data at the 2019 Crohn's & Colitis Congress

Feb 7, 2019

Health Catalyst Secures up to $100 Million with Financing Led By OrbiMed

Feb 7, 2019

Alector Announces Pricing of Initial Public Offering

Feb 7, 2019

Harpoon Therapeutics Announces Pricing of Initial Public Offering

Feb 6, 2019

Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering

Feb 6, 2019

Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs�CPI-444 and CPI-006 at Immuno-Oncology 360� Conference

Feb 6, 2019

resTORbio Appoints Erkan Baloglu, Ph.D., M.B.A., as Vice President of Drug Discovery and Medicinal Chemistry

Feb 6, 2019

HLS Therapeutics Announces Graduation to the Toronto Stock Exchange

Feb 5, 2019

Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock

Feb 5, 2019

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 5, 2019

Graybug Vision Appoints Frédéric Guerard as Chief Executive Officer Pharmaceutical Industry Veteran and Former Worldwide Business Franchise Head of Ophthalmology at Novartis

Feb 4, 2019

Avedro Launches Initial Public Offering

Feb 4, 2019

SI-BONE, Inc. Announces Additional Exclusive Coverage Policies for iFuse

Feb 4, 2019

Kyn Therapeutics Appoints Douglas Carlson as Chief Financial Officer

Feb 1, 2019

CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update

Jan 31, 2019

Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT Designation

Jan 29, 2019

scPharmaceuticals Inc. Announces Development Agreement with West Pharmaceutical Services for Next-Generation FUROSCIX� On-Body Infusor

Jan 28, 2019

Corvus Pharmaceuticals Announces Appointment of New Member of Board of Directors and Hiring of Chief Medical Officer

Jan 28, 2019

Xenon Provides Key Regulatory Updates on XEN007 and XEN1101

Jan 24, 2019

TELA Bio Announces First Patient in Europe Treated with OviTex® Reinforced BioScaffolds

Jan 24, 2019

Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors

Jan 23, 2019

ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial

Jan 23, 2019

Selecta Biosciences Announces Pricing of Public Offering of Common Stock

Jan 22, 2019

Selecta Biosciences Announces Proposed Public Offering of Common Stock

Jan 22, 2019

World's First MRIdian Center Celebrates Five Years of MRI-Guided Radiation Treatments

Jan 21, 2019

Graybug Vision Presents Top Line Results of Phase 1/2a ADAGIO Study at Hawaiian Eye & Retina 2019

Jan 18, 2019

Kala Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635C(4)

Jan 18, 2019

Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies

Jan 17, 2019

Terns Pharmaceuticals Announces the Appointment of Erin Quirk, M.D., as Chief Medical Officer

Jan 17, 2019

Promentis Pharmaceuticals Announces Commencement of Phase 2 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism

Jan 17, 2019

Tricida Announces Hiring of Susannah Cantrell, Ph.D., as Chief Commercial Officer

Jan 17, 2019

Proteus Digital Health® Launches Digital Oncology Medicines to Improve Patient Outcomes

Jan 17, 2019

Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy

Jan 16, 2019

Science Translational Medicine Publishes First-in-Human Clinical Data and Supporting Preclinical Data for SYNB1020, Synlogic’s Synthetic Biotic™ Medicine in Development as a Potential Treatment for Hyperammonemia

Jan 16, 2019

Alpine Immune Sciences Announces $25 Million Private Placement

Jan 16, 2019

Inspire Medical Systems, Inc. Announces a Positive Coverage Policy Issued by Horizon Blue Cross Blue Shield of New Jersey

Jan 14, 2019

Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment

Jan 14, 2019

Nabriva Therapeutics Provides Update on PDUFA Date for Intravenous CONTEPO™

Jan 14, 2019

Inspire Medical Systems, Inc. Announces First BCBS Coverage Policy following Evidence Street’s Positive Therapy Indication Summary

Jan 10, 2019

TELA Bio begins commercialization for Large Size OviTex® Reinforced BioScaffolds for Hernia Repair and Abdominal Wall Reconstruction after Aroa Biosurgery receives 510k clearance.

Jan 10, 2019

Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas

Jan 9, 2019

Adimab Provides 2018 Update on Clinical Pipeline

Jan 9, 2019

Venus Medtech Announces Agreement to Acquire Keystone Heart, LTD

Jan 9, 2019

Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554

Jan 8, 2019

Adimab Provides Year-End Update on 2018 Partnership Activities

Jan 8, 2019

Dr. Mary Kerr CEO NeRRe Therapeutics Presents at the Biotech Showcase, San Francisco

Jan 8, 2019

Corvus Announces Enrollment in Second Arm of Phase 1/1b Dose-Escalation Trial of Anti-CD73 Antibody, CPI-006, Focused on Combination with CPI-444 Adenosine Antagonist

Jan 7, 2019

KaNDy Therapeutics Announces the Appointmetn of Andrew Kay as Independent Chairman of the Board

Jan 7, 2019

Sublimity Therapeutics Receives Investigational New Drug (IND) Clearance from U.S. Food and Drug Administration (FDA)

Jan 7, 2019

Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches

Jan 7, 2019

Verrica Appoints Neil D. DeHenes as Vice President of Distribution, Trade and Channel Strategy

Jan 7, 2019

Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key Priorities

Jan 7, 2019

Gemini Therapeutics Announces the Initiation of CLARITY, a Disease Registry and Natural History Study of Subjects with Dry AMD and High-Risk Genotypes

Jan 7, 2019

ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2018 Results

Jan 7, 2019

Cyrus Bio announces full release of rapid and accurate protein mutational free energy tool in Cyrus Bench

Jan 7, 2019

Adimab Partner Innovent Receives Product Approval for PD-1 Antibody for Hodgkin's Lymphoma

Jan 7, 2019

Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews

Jan 7, 2019

Invitae reports 2018 preliminary financial results, delivering more than 100% volume and revenue growth in 2018; projects sustained growth in expanding markets through 2019 and beyond

Jan 7, 2019

Inspire Medical Systems, Inc. Announces a Positive Coverage Policy Issued by Horizon Blue Cross Blue Shield of New Jersey

Jan 7, 2019

Kala Pharmaceuticals Announces the Launch of Inveltys and the Hiring of a Specialty Ophthalmology Sales Organization

Jan 7, 2019

SI-BONE Reports Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2018

Jan 6, 2019

Xenon Pharmaceuticals Outlines 2019 Key Milestones

Jan 4, 2019

ViewRay Announces First Patient Enrolled in Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial for Locally Advanced Pancreatic Cancer

Jan 4, 2019

Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 4, 2019

Nabriva Therapeutics Provides Update on PDUFA Date for Intravenous CONTEPO™

Jan 3, 2019

Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs

Jan 3, 2019

Synlogic Progresses Clinical and Preclinical Pipeline and Outlines 2019 Catalysts

Jan 3, 2019

Audentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial Officer

Jan 3, 2019

Verona Pharma Appoints Kathleen Rickard, MD, as Chief Medical Officer to Lead Late Stage Clinical Development of RPL554

Jan 3, 2019

Selecta Biosciences Expands Potential for ImmTOR™ Platform and Streamlined Structure Under Leadership of New CEO, Carsten Brunn, Ph.D.

Jan 3, 2019

E-Scape Bio Appoints Dr. Carrolee Barlow as Chief Medical Officer

Jan 3, 2019

Verrica Achieves Positive Topline Results from Two Pivotal Phase 3 Clinical Trials of VP-102 in Patients with Molluscum Contagiosum

Jan 2, 2019

Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data From Its HPN424 Phase 1 Trial in Prostate Cancer

Jan 2, 2019

Nora Brennan Joins TELA Bio® as Chief Financial Officer

Our professional values trump net present values any day. OrbiMed is a collegial culture, working together for over 25 years in a collaborative, diverse, team-oriented environment.